<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003021" GROUP_ID="ADDICTN" ID="276100051510581467" MERGED_FROM="" MODIFIED="2009-02-16 13:17:42 +0100" MODIFIED_BY="Zuzana Mitrova" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;validation done the 17.08.2001&lt;/p&gt;" NOTES_MODIFIED="2009-02-16 13:17:12 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="10" REVMAN_SUB_VERSION="5.0.17" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.2">
<COVER_SHEET MODIFIED="2009-02-16 13:17:42 +0100" MODIFIED_BY="Zuzana Mitrova">
<TITLE>Treatment for amphetamine withdrawal</TITLE>
<CONTACT MODIFIED="2009-02-16 13:17:42 +0100" MODIFIED_BY="Zuzana Mitrova"><PERSON ID="BCEA0AC782E26AA20099EDD5ED6F7771" ROLE="AUTHOR"><FIRST_NAME>Steven</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Shoptaw</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>sshoptaw@mednet.ucla.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Family Medicine</DEPARTMENT><ORGANISATION>University of California</ORGANISATION><ADDRESS_1>10880 Wilshire Boulevard, Suite 540</ADDRESS_1><CITY>Los Angeles</CITY><ZIP>90024</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>310-794-0619 extension: 246</PHONE_1><FAX_1>310-794-2808</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-02-16 13:17:42 +0100" MODIFIED_BY="Zuzana Mitrova"><PERSON ID="BCEA0AC782E26AA20099EDD5ED6F7771" ROLE="AUTHOR"><FIRST_NAME>Steven</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Shoptaw</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>sshoptaw@mednet.ucla.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Family Medicine</DEPARTMENT><ORGANISATION>University of California</ORGANISATION><ADDRESS_1>10880 Wilshire Boulevard, Suite 540</ADDRESS_1><CITY>Los Angeles</CITY><ZIP>90024</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>310-794-0619 extension: 246</PHONE_1><FAX_1>310-794-2808</FAX_1></ADDRESS></PERSON><PERSON ID="9532CC1B82E26AA201B8424E1AC19BAF" ROLE="AUTHOR"><FIRST_NAME>Uyen</FIRST_NAME><LAST_NAME>Kao</LAST_NAME><EMAIL_1>UKao@mednet.ucla.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Family Medicine</DEPARTMENT><ORGANISATION>University of California</ORGANISATION><ADDRESS_1>10880 Wilshire Boulevard, Suite 540</ADDRESS_1><CITY>Los Angeles</CITY><ZIP>CA 90024</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>310 7940619</PHONE_1><FAX_1>310 7942808</FAX_1></ADDRESS></PERSON><PERSON ID="1D0AF36F82E26AA2002F1D7A5C57D5FD" ROLE="AUTHOR"><FIRST_NAME>Keith  </FIRST_NAME><LAST_NAME>Heinzerling</LAST_NAME><SUFFIX>MD, MPH</SUFFIX><EMAIL_1>kheinzerling@mednet.ucla.edu </EMAIL_1><ADDRESS><DEPARTMENT>Department of Family Medicine</DEPARTMENT><ORGANISATION>University of California</ORGANISATION><ADDRESS_1>10880 Wilshire Boulevard, Suite 540</ADDRESS_1><CITY>Los Angeles</CITY><ZIP>CA 90024</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>310 794-0619</PHONE_1><FAX_1>310 794-2808</FAX_1></ADDRESS></PERSON><PERSON ID="13360" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Walter</FIRST_NAME><LAST_NAME>Ling</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>lwalter@ucla.edu</EMAIL_1><ADDRESS><DEPARTMENT>Integrated Substance abuse Programs, Department of Psychiatry and Biobehavioral Sciences</DEPARTMENT><ORGANISATION>David Geffen School of Medicine at UCLA</ORGANISATION><ADDRESS_1>11075 Santa Monica Blvd., Ste. 200</ADDRESS_1><CITY>Los Angeles</CITY><ZIP>CA 90025</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+131 04799330</PHONE_1><FAX_1>+131 04799601</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-02-16 12:26:03 +0100" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Minor update: 26/11/03&lt;/p&gt;&lt;p&gt;New studies sought but none found: 04/11/03&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 16/12/00&lt;/p&gt;" NOTES_MODIFIED="2009-02-16 12:26:03 +0100" NOTES_MODIFIED_BY="Laura Amato">
<UP_TO_DATE>
<DATE DAY="9" MONTH="2" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="5" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="2" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2009-02-16 13:17:12 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-02-16 13:17:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>updated and conclusions changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-02-16 11:47:45 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>substantially updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-02-16 11:47:08 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR" MODIFIED="2008-05-20 23:29:56 +0100" MODIFIED_BY="Uyen H Kao">
<DATE DAY="25" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-16 11:47:08 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. Updated and new citation. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-08-28 22:50:21 +0100" MODIFIED_BY="Uyen H Kao">
<INTERNAL_SOURCES MODIFIED="2008-08-28 22:50:21 +0100" MODIFIED_BY="Uyen H Kao">
<SOURCE MODIFIED="2008-08-28 22:50:21 +0100" MODIFIED_BY="Uyen H Kao">
<NAME>UCLA Integrated Substance Abuse Programs</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-02-16 12:06:46 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-02-16 12:06:46 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-17 21:22:18 +0100" MODIFIED_BY="Uyen H Kao">Treatment for amphetamine withdrawal</TITLE>
<SUMMARY_BODY MODIFIED="2009-02-16 12:06:46 +0100" MODIFIED_BY="[Empty name]">
<P>Symptoms of amphetamine withdrawal during the initial days of abstinence from chronic amphetamine use can prompt individuals to return to regular drug use. No medications demonstrate significant effects over placebo in reducing symptoms of acute amphetamine withdrawal.<BR/>
<BR/>Amphetamines can make people feel more alert, and are prescribed for problems like depression and attention deficit order. Amphetamines can produce euphoria, and so are manufactured for recreational use. Ongoing use can lead to dependence, which can be as hard to recover from as dependence on heroin or cocaine.  The only randomized trials of amphetamine withdrawal agents have been of antidepressant drugs (amineptine and mirtazapine).   Amineptine was found to have limited benefits, showing improvement only on some subjective effects but is no longer on the market because of concerns over its abuse liability. The benefits of mirtazapine have been less clear based on two randomised controlled trials, with one showing improvements in amphetamine withdrawal symptoms and the other showing no differences in withdrawal outcomes when compared to placebo.  More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-02-16 12:01:06 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-02-16 11:57:21 +0100" MODIFIED_BY="[Empty name]">
<P>Few studies examined treatments for amphetamine withdrawal, although it is a common problem among amphetamine users. Its symptoms, in particular intense craving, may be a critical factor leading to relapse to amphetamine use. In clinical practice, medications for cocaine withdrawal are commonly used to manage amphetamine withdrawal although the pharmacodynamic and pharmacokinetic properties of these two illicit substances are different.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-02-11 19:50:13 +0100" MODIFIED_BY="Uyen H Kao">
<P>To assess the effectiveness of pharmacological alone or in combination with psychosocial treatment for amphetamine withdrawals on discontinuation rates, global state, withdrawal symptoms, craving, and other outcomes. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-21 22:05:01 +0100" MODIFIED_BY="Uyen H Kao">
<P>MEDLINE (1966 - 2008), CINAHL (1982 - 2008), PsycINFO (1806 - 2008), CENTRAL (Cochrane Library 2008 issue 2), references of obtained articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-02-16 11:59:52 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled and clinical trials evaluating pharmacological and or psychosocial treatments (alone or combined) for people with amphetamine withdrawal symptoms.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-02-16 12:01:06 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors evaluated and extracted data independently. The data were extracted from intention-to-treat analyses. The Relative Risk (RR) with the 95% confidence interval (95% CI) was used to assess dichotomous outcomes. The Weighted Mean Difference (WMD) with 95% CI was used to assess continuous outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-01-05 20:07:16 +0100" MODIFIED_BY="Uyen H Kao">
<P>Four randomised controlled trials (involving 125 participants) met the inclusion criteria for the review. Two studies found that amineptine significantly reduced discontinuation rates and improved overall clinical presentation, but did not reduce withdrawal symptoms or craving compared to placebo. The benefits of mirtazapine over placebo for reducing amphetamine withdrawal symptoms were not as clear.  One study suggested that mirtazapine may reduce hyperarousal and anxiety symptoms associated with amphetamine withdrawal. A more recent study failed to find any benefit of mirtazapine over placebo on retention or on amphetamine withdrawal symptoms.  </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-02-04 22:31:43 +0100" MODIFIED_BY="[Empty name]">
<P>No medication is effective for treatment of amphetamine withdrawal. Amineptine showed reduction in discontinuation rates and improvement in clinical presentation compared to placebo, but had no effect on reducing withdrawal symptoms or craving. In spite of these limited benefits, amineptine is not available for use due to concerns over abuse liability when using the drug. The benefits of mirtazapine as a withdrawal agent are less clear based on findings from two randomised controlled trials: one report showed improvements in amphetamine withdrawal symptoms over placebo; a second report showed no differences in withdrawal symptoms compared to placebo.  Further potential treatment studies should examine medications that increase central nervous system activity involving dopamine, norepinephrine and/or serotonin neurotransmitters, including mirtazapine.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-02-16 12:02:43 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-02-16 12:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>Although there are a variety of amphetamines and amphetamine derivatives, the word "amphetamines" in this review stands for amphetamine, dextroamphetamine, and methamphetamine.<BR/>
</P>
<CONDITION MODIFIED="2009-02-16 12:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>When chronic heavy users abruptly discontinue amphetamine use, many report a time-limited withdrawal syndrome that occurs within 24 hours of their last dose. Withdrawal symptoms are sufficiently severe to cause relapse to drug use in the absence of contained environments. The prevalence of this withdrawal syndrome is extremely common (<LINK REF="REF-Cantwell-1998" TYPE="REFERENCE">Cantwell 1998</LINK>; <LINK REF="REF-Gossop-1982" TYPE="REFERENCE">Gossop 1982</LINK>) with 87.6% of 647 individuals with amphetamine dependence reporting six or more signs of amphetamine withdrawal listed in the DSM when the drug is not available (<LINK REF="REF-Schuckit-1999" TYPE="REFERENCE">Schuckit 1999</LINK>). The DSM-IV-TR criteria for diagnosing amphetamine withdrawal include dysphoric mood and two or more symptoms: fatigue, vivid or unpleasant dreams, insomnia or hypersomnia, increased appetite and psychomotor agitation or retardation that occur following discontinuation of the drug (<LINK REF="REF-DSM_x002d_IV_x002d_TR-2000" TYPE="REFERENCE">DSM-IV-TR 2000</LINK>). Clinically, amphetamine dependent individuals in acute withdrawal report feeling &#8220;severe dysphoria, irritability and melancholia, anxiety, hypersomnia and marked fatigue, intense craving for the drug and paranoia.&#8221; Factor analysis of withdrawal symptoms indicate this clinical condition may be comprised of three factors (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A>): A hyperarousal factor comprised of drug craving, agitation, and vivid or unpleasant dreams, a reversed vegetative factor comprised of decreased energy, increased appetite, and increased craving for sleep, and an anxiety factor comprised loss of interest or pleasure, anxiety and slowing of movement.</P>
<P>The experience of withdrawal from amphetamines is clinically severe and it is during this period that reports of suicidal ideation and attempts are noted (<LINK REF="REF-Meredith-2005" TYPE="REFERENCE">Meredith 2005</LINK>; <LINK REF="REF-Scott-2007" TYPE="REFERENCE">Scott 2007</LINK>). Amphetamine dependent individuals trying to discontinue or to cut down use of the drug using self-help or even formal treatment commonly relapse, as a single use of amphetamine immediately removes discomfort and institutes a sense of well-being or euphoria (<LINK REF="REF-Rawson-2002" TYPE="REFERENCE">Rawson 2002</LINK>). As the initial phase of treatment requires cessation of use, amphetamine withdrawal compromises long-term success for some individuals with severe amphetamine dependence to achieve protracted abstinence.</P>
<P>The severity of withdrawal symptoms is greater in amphetamine dependent individuals who are older and who have more extensive amphetamine use disorders (<LINK REF="STD-McGregor-2005" TYPE="STUDY">McGregor 2005</LINK>). Withdrawal symptoms typically present within 24 hours of the last use of amphetamine, with a withdrawal syndrome involving two general phases that can last 3 weeks or more. The first phase of this syndrome is the initial &#8220;crash&#8221; that resolves within about a week (<LINK REF="REF-Gossop-1982" TYPE="REFERENCE">Gossop 1982</LINK>; <LINK REF="STD-McGregor-2005" TYPE="STUDY">McGregor 2005</LINK>). The most immediate symptoms occur during this &#8220;crash&#8221; period and are observed to resolve during the first week of abstinence measured using total scores of the clinician rated Amphetamine Withdrawal Questionnaire, the Amphetamine Selective Severity Assessment and the staff rated Clinical Global Impressions (<LINK REF="STD-McGregor-2005" TYPE="STUDY">McGregor 2005</LINK>). Severe symptoms in the &#8220;crash&#8221; phase of amphetamine withdrawal include increases in sleep (averaging 2-3 hours more per night than controls, but with poor sleep quality, light sleep, frequent awakening, and not feeling clearheaded on arising), increases in appetite, and decreases in complaints of depression (<LINK REF="STD-McGregor-2005" TYPE="STUDY">McGregor 2005</LINK>; <LINK REF="REF-Newton-2004" TYPE="REFERENCE">Newton 2004</LINK>). A subacute, protracted set of withdrawal symptoms that generally resolve in 3 weeks and that are not as well defined, include continued sleep disturbances (mild hypersomnia or insomnia and continued increased appetite (<LINK REF="STD-McGregor-2005" TYPE="STUDY">McGregor 2005</LINK>;<LINK REF="REF-Gossop-1982" TYPE="REFERENCE">Gossop 1982</LINK>). Although the most severe symptoms occurring during amphetamine withdrawal resolve in a week or less, some symptoms may continue for weeks or months (<LINK REF="REF-Watson-1972" TYPE="REFERENCE">Watson 1972</LINK>; <LINK REF="REF-Hofmann-1983" TYPE="REFERENCE">Hofmann 1983</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-01-05 19:25:17 +0100" MODIFIED_BY="Uyen H Kao">
<P>Symptoms of amphetamine withdrawal are time limited, with most resolving in a week. Thus, a treatment for amphetamine withdrawal needs rapid onset. In clinical practice and in the studies reviewed, treatment is started as soon as possible following the last dose of amphetamine. Medication is continued for up to two weeks to provide symptomatic relief. In addition to medication, it can be helpful to provide psychosocial and/or behavioral treatments for stimulant abuse to assist the patient in amphetamine withdrawal in sustaining abstinence from amphetamine once their treatment is completed (<LINK REF="REF-Lee-2008" TYPE="REFERENCE">Lee 2008</LINK>). Following brief exposure to the treatment, the medication is discontinued regardless of response as there is no evidence to suggest a pharmacotherapy for amphetamine withdrawal would have efficacy for amphetamine abuse or dependence.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-01-05 19:09:49 +0100" MODIFIED_BY="Uyen H Kao">
<P>One rationale guiding selection of medications for amphetamine withdrawal involves using a medication to stabilize dopamine, norepinephrine or serotonin neurotransmission to provide relief from withdrawal symptoms. According to this rationale, the neurobiology of the amphetamine withdrawal syndrome and its relief would be related to the cumulative effects of repeated exposure of neurons to high dose amphetamines (<LINK REF="REF-Meredith-2005" TYPE="REFERENCE">Meredith 2005</LINK>). Initial &#8220;highs&#8221; mediated by extracellular dopamine and norepinephrine levels in striatum (midbrain) become attenuated. Aspects of the withdrawal syndrome may be mediated by different neurotransmitter systems that include dopamine, norepinephrine and serotonin. Diminished dopamine synaptic transmission in acute withdrawal may be responsible for anhedonia and psychomotor retardation. As well, decreased synaptic serotonin availability may be the substrate for depressed mood, obsessive thoughts about the drug and lack of impulse control (<LINK REF="REF-Rothman-2007" TYPE="REFERENCE">Rothman 2007</LINK>). Medications that acutely stabilize neurotransmission in these systems may relieve acute withdrawal symptoms and assist the patient in establishing relevant periods of amphetamine abstinence.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-02-16 11:53:39 +0100" MODIFIED_BY="[Empty name]">
<P>In 2006, 24.7 million individuals aged 15-64 consumed amphetamine type stimulants (<LINK REF="REF-UNODC-2008" TYPE="REFERENCE">UNODC 2008</LINK>). Among chronic users of amphetamines, evidence is accruing to describe the range of public health problems attributable to sustained heavy use of the drug. Medical consequences of chronic use of amphetamines include cardiovascular insults, cognitive dysfunction and infectious disease (<LINK REF="REF-Meredith-2005" TYPE="REFERENCE">Meredith 2005</LINK>; <LINK REF="REF-Pasic-2007" TYPE="REFERENCE">Pasic 2007</LINK>). Development of one or more medications for amphetamine withdrawal, particularly if implemented with evidence-based behavioral or counselling interventions, would have great public health significance. Maintaining a review of outcomes from experiences using medications in clinical trials for amphetamine withdrawal is an important method for clinicians to stay current and to seek guidance regarding medication strategies when treating individuals in acute withdrawal from amphetamines.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-02-11 19:50:31 +0100" MODIFIED_BY="Uyen H Kao">
<P>To assess the effectiveness of pharmacological alone or in combination with psychosocial treatment for amphetamine withdrawals on discontinuation rates, global state, withdrawal symptoms, craving, and other outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-02-16 11:49:06 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-17 21:29:37 +0100" MODIFIED_BY="Uyen H Kao">
<CRIT_STUDIES MODIFIED="2008-08-28 00:44:18 +0100" MODIFIED_BY="Uyen H Kao">
<P>All relevant randomised controlled trials (RCTs) and clinical controlled trials (CCTs) were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-17 19:17:15 +0100" MODIFIED_BY="Uyen H Kao">
<P>Individuals with amphetamine withdrawal, diagnosed by any set of criteria. Individuals experiencing withdrawal from other substances in addition to amphetamine withdrawal are included only if:</P>
<OL>
<LI>The data for amphetamine withdrawal are reported separately, or</LI>
<LI>More than half of the participants are amphetamine withdrawal patients.</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-17 16:36:06 +0100" MODIFIED_BY="Uyen H Kao">
<P>Experimental intervention: Any kind of pharmacological treatment, alone or in combination with a psychosocial treatment</P>
<P>Control intervention: Placebo or any kind of psychosocial treatment alone<BR/>
</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-17 21:29:37 +0100" MODIFIED_BY="Uyen H Kao">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-17 21:28:49 +0100" MODIFIED_BY="Uyen H Kao">
<OL>
<LI>Discontinuation rate measured as number of participants who did not complete the treatment</LI>
<LI>Average score in global state as measured by global psychiatric rating scales, e.g. Clinical Global Impression</LI>
<LI>Average score in withdrawal symptoms as measured by withdrawal symptomology assessments, e.g. Amphetamine Withdrawal Questionnaire</LI>
<LI>Average score in craving as measured by craving rating scales, e.g. Questionnaire for Evaluating Cocaine Craving and Related Responses, Visual Analog Scale, Brief Substance Craving Scale</LI>
<LI>Patient satisfaction as measured by type and number of adverse events</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-17 21:29:37 +0100" MODIFIED_BY="Uyen H Kao">
<OL>
<LI>Duration of adherence to treatment as measured by pill count or self-report adherence</LI>
<LI>Death as measured by the number of reported mortality</LI>
</OL>
<P>All outcomes were reported for the short term (4 weeks or 1 month), medium term (more than 4 weeks or 1 month to 12 weeks or 3 months), and long term (more than 3 months). If any outcome was assessed more than once in a particular term, only the results of the longest duration in that term were considered.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-22 01:51:45 +0100" MODIFIED_BY="Uyen H Kao">
<P>The search incorporated a number of methods to identify completed and ongoing studies</P>
<ELECTRONIC_SEARCHES MODIFIED="2008-10-21 22:08:40 +0100" MODIFIED_BY="Uyen H Kao">
<UL>
<LI>We originally searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2000, issue 4, MEDLINE (January 1966 to December 2000) and EMBASE (January 1980 to December 2000).</LI>
<LI>For this updated version we searched CENTRAL through 2008, Issue 2 of <I>The Cochrane Library</I>, and MEDLINE, PsycINFO and CINAHL through to May 1, 2008. For details <I>see</I> <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-22 01:51:45 +0100" MODIFIED_BY="Uyen H Kao">
<P>We also searched:</P>
<UL>
<LI>the reference lists of all relevant papers to identify further studies.</LI>
<LI>some of the main electronic sources of ongoing trials (Current Controlled Trials - http://www.controlled-trials.com/, Clinical Trials.gov, Trialsjournal.com)</LI>
<LI>conference proceedings likely to contain trials relevant to the review.</LI>
</UL>
<P>We contracted investigators seeking information about unpublished or incomplete trials.</P>
<P>All searches included non-English language literature and studies with English abstracts were assessed for inclusion. When considered likely to meet inclusion criteria, studies were translated.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-02-16 11:49:06 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-10-17 21:31:30 +0100" MODIFIED_BY="Uyen H Kao">
<P>In the original review, reports identified by the electronic searches were assessed for relevance. Two reviewers (MS &amp; NJ) independently inspected all study citations identified by the electronic searches and full reports of the studies of agreed relevance were obtained. Where disputes arose the full reports were acquired for more detailed scrutiny. The reviewers (MS &amp; NJ) then independently inspected all these full study reports.</P>
<P>For this update of the review, one author (UK) inspected the search hits by reading titles and abstracts. Each potentially relevant study located in the search was obtained in full text and assessed for inclusion independently by two authors (SS &amp; UK). Discrepancies were resolved by discussion between the authors.</P>
<P>The corresponding author was contacted if information necessary for the review was not available in the reports.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-01-05 20:30:34 +0100" MODIFIED_BY="Uyen H Kao">
<P>Data were extracted independently by the authors onto data extraction forms. Again, if disputes arose, these were resolved either by discussion between the two reviewers or the correspondence author of the paper.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-02-16 11:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>We changed the criteria to assess the methodological quality of included studies to conform the review to the recommended methods outlined in the last Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and to the request of RevMan 5. We assessed the new studies included in the updated version and we reassessed the studies already included in the old review using the new criteria. The new criteria were based on the following specific domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other issues. We evaluated the included studies as follow:</P>
<P>A. Sequence generation was assessed for all outcomes. Studies were considered at low risk of bias if they provided a clear method of generating an allocation sequence to produce comparable groups, i.e. random number table, computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice. Studies were considered at high risk of bias if they used some systematic, non-random approach, i.e. date of birth, date of admission, clinic record number, by clinician.</P>
<P>B. Allocation concealment was assessed for all outcomes. Studies were considered at low risk of bias if they provided adequate allocation concealment, i.e. central allocation including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes. Studies were determined at high risk of bias if they had inadequate allocation concealment, i.e. using an open random allocation schedule such as a list of random numbers; assignment envelopes were used without appropriate safeguards e.g. if envelopes were unsealed or non-opaque or not sequentially numbered; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
<P>C. Blinding of participants, personnel, and outcome assessor was considered separately for objective outcomes (discontinuation rates) and subjective outcomes (global state, craving, and withdrawal symptoms). For discontinuation rates, we judged that lack of blinding was unlikely to influence data collection.</P>
<P>D. Incomplete outcome data were considered for all outcomes except for discontinuation rates. It was assessed for results at the end of the study period. Studies were considered at low risk of bias if they adequately addressed missing data.</P>
<P>E. Selective outcome reporting was considered for all outcomes except for discontinuation rates.</P>
<P>Studies were judged to have unclear risk of bias if there was insufficient information to permit judgment of 'low' or 'high' risk of bias for each of the domains.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-10-17 21:32:10 +0100" MODIFIED_BY="Uyen H Kao">
<P>Other than raw data (e.g. death), the outcomes derived from only valid scales were included in the reviews. In this review, a valid scale means a scale that has been published in a scientific journal.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-02-16 11:49:06 +0100" MODIFIED_BY="[Empty name]">
<P>Test of heterogeneity is important to check whether the results of studies are similar within each comparison. The reviewers checked whether differences between the results of trials were greater than could be expected by chance alone. This was done by looking at the graphical display of the results but also by using Chi square tests of heterogeneity. A p-value being less than 0.05 of a Chi-square test was indicated the significant heterogeneity of a data set. The statistical methods for dealing with a data set with significant and non significant heterogeneity were described in 'Data synthesis'. In addition, the causes possibly leading to the significant heterogeneity of a data set were discussed.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-10-17 21:33:00 +0100" MODIFIED_BY="Uyen H Kao">
<P>
<I>Dichotomous data:</I> The Relative Risk (RR) with the 95% confidence interval (95% CI) was used. RR is the ratio of risk in the intervention group to the risk in the control group. The risk (proportion, probability or rate) is the ratio of people with an event in a group to the total in the group. A relative risk of one indicates no difference between comparison groups. For undesirable outcomes a RR that is less than one indicates that the intervention was effective in reducing the risk of that outcome.</P>
<P>In addition, as a measure of efficacy, the number needed to treat (NNT) was also calculated. The reviewers extracted the dichotomous data on an intention-to-treat basis by applying the following guidelines to analyse data from included studies: (i) the analysis included all those who entered the trial; and (ii) the analysis maintained the study groups according to the original randomisation procedure. The reviewers assigned people lost to follow-up to the worst outcome.</P>
<P>
<I>Continuous data: </I>The Weighted Mean Difference (WMD) with 95% CI was used. WMD is a method of meta-analysis used to combine measures on continuous scales (such as weight), where the mean, standard deviation and sample size in each group are known. The weight given to each study (e.g. how much influence each study has on the overall results of the meta-analysis) is determined by the precision of its estimate of effect and, in the statistical software in RevMan and CDSR, is equal to the inverse of the variance. This method assumes that all of the trials have measured the outcome on the same scale.</P>
<P>For the studies in which the treatment and/or controlled groups were divided into subgroups because of the differences of concurrent treatment, the continuous data of the subgroups receiving more rigorous treatment, e.g., higher doses of drug treatment, more intensive psychotherapy, were extracted.</P>
<P>In conducting a meta-analysis, a fixed effect model, an analysis that ignores the between-study variation, can give a narrower confidence interval than a random effect model. It is generally agreed that the fixed effect model is valid as a test of significance of the overall null hypothesis (i.e. 'no effect in all studies'). A statistically significant result obtained by the use of this model indicated that there is an effect in at least one of the studies. Because of these advantages, the fixed effect model was used for the synthesis of a group of data with homogeneity. Although a random effect model can be applied for the synthesis of a group of data with significant heterogeneity, the results obtained by the synthesis of this group of data have to be interpreted with great caution.</P>
<P>As high attrition rate would affect the study results, the studies with the attrition rate of 50% or higher of the total participants were excluded.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-10-17 21:33:12 +0100" MODIFIED_BY="Uyen H Kao">
<P>Sensitivity analysis is an analysis used to determine how sensitive the results of a study or systematic review are to changes in how it was done. Sensitivity analyses are used to assess how robust the results are to uncertain decisions or assumptions about the data and the methods that were used.</P>
<P>The reviewers examined whether the decision to include the data obtained from studies in which most (50%-75%) participants were amphetamine dependent or abuse affected the results of review. The sensitivity analyses were done by the inclusion and exclusion of the data obtained from these studies. If both analyses point to the same conclusion in the respect of significant heterogeneity of data, the meta-analyses including the data obtained from these studies were taken into consideration. Otherwise, the meta-analyses conducted by the exclusion of the data obtained from these studies were considered.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-02-16 11:55:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-02-16 11:54:30 +0100" MODIFIED_BY="[Empty name]">
<P>See: Characteristics of included studies; Characteristics of excluded studies.</P>
<SEARCH_RESULTS MODIFIED="2008-10-22 01:29:22 +0100" MODIFIED_BY="Uyen H Kao">
<P>The search strategy resulted in the identification of 1146 studies, 1137 references were excluded on basis of title and abstract and 9 were retrieved for more detailed evaluation, <I>see</I> <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-02-16 11:54:30 +0100" MODIFIED_BY="[Empty name]">
<P>Four studies, involving 125 participants, met the inclusion criteria for this review (<I>see </I>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).  In total, 59 participants received treatment for amphetamine withdrawal (37 amineptine, 22 mirtazapine) compared to 66 participants who received placebo.  </P>
<SUBSECTION>
<HEADING LEVEL="6">Comparisons</HEADING>
<P>Of the four studies that met the inclusion criteria, two studies compared amineptine with placebo (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0001">Jittiwutikan 1997</A>; <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A>) and two studies compared mirtazapine with placebo (<LINK REF="STD-Kongsakon-2005" TYPE="STUDY">Kongsakon 2005</LINK>; <LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>).  Amineptine is an atypical tricyclic antidepressant that selectively inhibits the reuptake of dopamine and norepinephrine.  Because amineptine has similar mechanism of actions as amphetamines, it was put forth that amineptine could help to relieve amphetamine withdrawal symptoms. Mirtazapine, a noradrenergic and specific serotonergic antidepressant, was also hypothesized to help reduce methamphetamine withdrawal severity by blocking the presynaptic alpha-2 adrenergic receptors that inhibit the release of norepinephrine and serotonin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Treatment setting</HEADING>
<P>Of the four studies that met the inclusion criteria, two (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0001">Jittiwutikan 1997</A>, <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A>) were conducted at a drug dependence treatment center, one (<LINK REF="STD-Kongsakon-2005" TYPE="STUDY">Kongsakon 2005</LINK>) at a probation facility, and one (<LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>) in a public drug and alcohol outpatient clinic.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Participant characteristics</HEADING>
<P>The participants of the four included studies were mainly males (110 males, 15 females).  In two studies (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0001">Jittiwutikan 1997</A>, <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A>), participants were inpatients at a drug dependence treatment center who met DSM-IV criteria for amphetamine withdrawal. In the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A> study, participants had to meet the additional criteria of having an Amphetamine Withdrawal Questionnaire (AWQ) score of 10 or higher.  The combined mean duration of amphetamine use histories and length of time since last use of amphetamine prior to admission for the two studies on amineptine was 23.6 months and 55.2 hours, respectively.  The average age of the participants was 19.1 years.  Participants in the <LINK REF="STD-Kongsakon-2005" TYPE="STUDY">Kongsakon 2005</LINK> study were detainees from a probation facility who were diagnosed with amphetamine dependence by DSM-IV criteria.  All the participants in this study were males and had an average age of 24.3 years. Participants in the <LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK> study were those that met DSM-IV criteria for amphetamine dependence, reported using amphetamine or methamphetamine within the last 72 hours, and were recruited from two drug and alcohol out-patient clinics.   </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Treatment regimes</HEADING>
<P>Two studies (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A>; <LINK REF="STD-Jittiwutikan-1997" TYPE="STUDY">Jittiwutikan 1997</LINK>) administered 300 mg of amineptine per day, given orally in two 100 mg capsules after breakfast and one 100 mg capsule after lunch.  In these two studies, low dose of lorazepam was administered on occasion to patients with moderate to severe anxiety or insomnia.   One study (<LINK REF="STD-Kongsakon-2005" TYPE="STUDY">Kongsakon 2005</LINK>) administered a dose range of 15-60 mg per day of mirtazapine with an initial dose of 15 mg.  Dose titrations during this study were based on the subjects&#8217; clinical response to the medication.  No medication other than mirtazapine was used according to the study report.  In another study (<LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>), participants were administered 15 mg of mirtazapine on the first two nights and 30 mg mirtazapine every night for the next 12 nights.  In all four studies (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A>; <LINK REF="STD-Jittiwutikan-1997" TYPE="STUDY">Jittiwutikan 1997</LINK>, <LINK REF="STD-Kongsakon-2005" TYPE="STUDY">Kongsakon 2005</LINK>; <LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>), the treatment duration was 14 days.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-10-17 19:59:13 +0100" MODIFIED_BY="Uyen H Kao">
<P>Five studies did not meet the criteria for inclusion in this review (<LINK REF="STD-Gillin-1994" TYPE="STUDY">Gillin 1994</LINK>; <LINK REF="STD-McGregor-2008a" TYPE="STUDY">McGregor 2008a</LINK>; <LINK REF="STD-McGregor-2005" TYPE="STUDY">McGregor 2005</LINK>; <LINK REF="STD-Chan_x002d_Ob-2001" TYPE="STUDY">Chan-Ob 2001</LINK>; <LINK REF="STD-Cox-2004" TYPE="STUDY">Cox 2004</LINK>). The reasons for exclusions are described in &#8220;Characteristics of excluded studies.&#8221;</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-02-11 19:24:50 +0100" MODIFIED_BY="Uyen H Kao">
<P>Summary of results across studies for each domain are illustrated in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2008-10-22 00:13:55 +0100" MODIFIED_BY="Uyen H Kao">
<P>One study was judged to be at low risk of bias and three studies were judged to be at unclear risk of bias. </P>
</ALLOCATION>
<BLINDING MODIFIED="2009-02-11 19:24:50 +0100" MODIFIED_BY="Uyen H Kao">
<P>For objective outcomes (discontinuation rates), blindness of participants, personnel, and outcome assessors differed across studies. Because we judged that the objective outcome was unlikely to be influenced by the lack of blinding, all studies were determined to be at low risk of bias. </P>
<P>For subjective outcomes (global state, craving, and withdrawal symptoms), blindness of participants, personnel, and outcome assessors were conducted in only one study and was determined to be at low risk of bias. In two studies, it was unclear if the outcome assessors were blinded in addition to the participants and personnel. Hence, we judged them to be at unclear risk of bias. One study did not specify any method of blinding and was determined to be at unclear risk of bias. </P>
</BLINDING>
<EXCLUSIONS MODIFIED="2008-10-22 00:13:21 +0100" MODIFIED_BY="Uyen H Kao">
<P>All studies were judged to be at low risk of bias. Three studies performed a last observation carried forward method of intent-to-treat analysis and one study had a drop out rate that was balanced across intervention groups. </P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2008-10-22 01:25:45 +0100" MODIFIED_BY="Uyen H Kao">
<P>All included studies were judged as being low risk of bias. See risk of bias tables in the "Characteristics of included studies" table. </P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-02-16 11:55:52 +0100" MODIFIED_BY="[Empty name]">
<P>Four studies met the criteria to be included in this review (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A>; <LINK REF="STD-Jittiwutikan-1997" TYPE="STUDY">Jittiwutikan 1997</LINK>; <LINK REF="STD-Kongsakon-2005" TYPE="STUDY">Kongsakon 2005</LINK>; <LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>). The results were summarized, with comparison of quantitative data where possible, between any pharmacological treatments (amineptine, mirtazapine) and placebo at the end of the 14-day medication period. Outcomes were reported based on available data.</P>
<P>(1)   Discontinuation rate</P>
<P>In all four studies involving 125 participants, the discontinuation rate was defined as the number of participants who did not complete the study.  Overall, a significant difference in discontinuation rates was observed between treatment and placebo groups (RR 0.52, 95% CI 0.29 to 0.94) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).  The results indicated that participants receiving any active treatment, but particularly amineptine, were significantly less likely to discontinue the study as compared to those receiving placebo.  Hetereogeneity among the four studies was considered moderate but not statistically significant (I<SUP>2</SUP>=45%, p=0.14).  The moderate level of heterogeneity among the studies was related to the treatment medication used (amineptine versus mirtazapine). See <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>
</P>
<P>(2) Average score in global state</P>
<P>The average score in global state was reported in three of the four included studies.  Two studies (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A>; <LINK REF="STD-Jittiwutikan-1997" TYPE="STUDY">Jittiwutikan 1997</LINK>) used the Clinical Global Impression or CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) and one (<LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>) used the Brief Symptom Inventory Global Severity Index sub scale or BSI-GSI (<LINK REF="REF-Derogatis-1993" TYPE="REFERENCE">Derogatis 1993</LINK>) to measure global state.  For both CGI and BSI-GSI, a higher score indicates greater severity.</P>
<P>The data from the three studies, involving 103 participants, were significantly heterogenous (I<SUP>2</SUP>=69%, p=0.04).  The heterogeneity was most likely related to the difference in treatment medication (amineptine versus mirtazapine) and measurements used (CGI versus BSI-GSI) among the studies, therefore a combined result was not calculated.   </P>
<P>However, in a subgroup analysis between amineptine and placebo, the Weighted Mean Difference (WMD) was -0.49 (95% CI -0.80 to -0.17), showing that participants receiving amineptine was significantly more likely to improve in global state than placebo (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).  No difference was found between mirtazapine and placebo (WMD 0.30, 95% CI -0.22 to 0.82) based on the data of one study (<LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>).  <LINK REF="STD-Kongsakon-2005" TYPE="STUDY">Kongsakon 2005</LINK> did not report data on global state, hence it was not included in the analysis. See <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>
</P>
<P> (3) Average score in withdrawal symptoms</P>
<P>Although three studies reported data on withdrawal symptoms, only two studies involving 74 participants were included in the analysis (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A>; <LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>).  Data from <LINK REF="STD-Kongsakon-2005" TYPE="STUDY">Kongsakon 2005</LINK> for this specific outcome were not used because only median withdrawal scores were reported and means and standard deviations were needed for the comparison.  However, the study did report significant improvements in amphetamine withdrawal symptoms as measured by the Amphetamine Withdrawal Questionnaire (AWQ) in the mirtazapine group versus placebo.</P>
<P>
<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0002">Srisurapanont 1999b</A> used the AWQ, which is a 10-item, self-administered instrument based on the DSM-IV withdrawal criteria (<LINK REF="REF-Srisurapanont-1999a" TYPE="REFERENCE">Srisurapanont 1999a</LINK>).   <LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>, on the other hand, used the Amphetamine Cessation Symptoms Assessment or ACSA (<LINK REF="REF-McGregor-2008b" TYPE="REFERENCE">McGregor 2008b</LINK>) to measure withdrawal symptoms. The ACSA is a 16-item, self-administered instrument including 9 of the 10 items from the AWQ and 13 of the 18 items from a modified Cocaine Selective Severity Assessment (the word &#8220;cocaine&#8221; was replaced with &#8220;amphetamines&#8221;).  For both the AWQ and ACSA, higher numbers indicate greater withdrawal symptom severity.</P>
<P>The Standardised Mean Difference (SMD) for the two studies involving 74 participants was -0.08 (95% CI -0.54 to 0.38), showing no difference between treatment group and placebo in reducing withdrawal symptoms (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). See<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>
</P>
<P>(4) Average score in craving</P>
<P>One study (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0001">Jittiwutikan 1997</A>), involving 29 participants, reported data on craving using the Questionnaire for Evaluating Cocaine Craving and Related Responses or QECCRR (<LINK REF="REF-Voris-1991" TYPE="REFERENCE">Voris 1991</LINK>).  The QECCRR was developed to separately measure four respects of cocaine withdrawal, including craving, depressed mood, no energy and sick feeling. Only the craving score of QECCRR was used in the analysis.  For this measure, a high score indicates less severity in craving.  The WMD was 0.43 (95% CI -1.23 to 2.09) and was not statistically significant (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). See <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>
</P>
<P>In summary, the results showed some benefits of amineptine in the treatment of amphetamine withdrawal, as seen in the discontinuation rate and improvements in the global state as measured by CGI.  There were no direct benefits of amineptine on withdrawal symptoms or craving.  Mirtazapine was no more effective than placebo in terms of discontinuation rate, improvements on global state, and reduction in withdrawal symptoms based on the results of one study (<LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>).  <BR/>
<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-02-16 11:49:45 +0100" MODIFIED_BY="[Empty name]">
<P>Amphetamine withdrawal occurs commonly among amphetamine users and has clinical relevance as the symptoms may prompt relapse to amphetamine use as a means of symptom relief. Yet few well controlled studies have examined pharmacologic treatments for amphetamine withdrawal. To date, only amineptine and mirtazapine have been studied for treating this condition using placebo-controls, blinding and randomisation. Amineptine is a central stimulant and dopamine reuptake inhibitor with biochemical and pharmacological effects similar to those of amphetamine (<LINK REF="REF-Samanin-1977" TYPE="REFERENCE">Samanin 1977</LINK>). Amineptine was initially used as an antidepressant in France; availability of amineptine was limited in other countries. Amineptine was voluntarily withdrawn from the market in 1999 due to reports of amineptine abuse. Mirtazapine is an antidepressant with a relatively good tolerance and safety profile.  It has been approved by the U.S. Food and Drug Administration and is commonly used to treat moderate to severe depression.  Mirtazapine is a tetracyclic piperazinoazepine that enhances central noradrenergic and serotonergic activity by blocking alpha<SUB>2</SUB> receptors and selectively antagonizing 5HT<SUB>2</SUB> and 5HT<SUB>3</SUB> receptors (<LINK REF="REF-De-Boer-1996" TYPE="REFERENCE">De Boer 1996</LINK>).  Mirtazapine has also shown to improve suicidal ideation, to show relatively few side effects, and to show little abuse potential.<BR/>
<BR/>The results of this review suggest that amineptine has some limited benefits in increasing the adherence to treatment and improving general condition but has no direct benefit on specific amphetamine withdrawal symptoms or craving. As amineptine has been withdrawn from the market, additional studies and clinical development of amineptine for amphetamine withdrawal are not warranted. We found no effect for mirtazapine on adherence to treatment, general condition, amphetamine withdrawal symptoms, or cravings. However, this result was based on data of one study (<LINK REF="STD-Cruickshank-2008" TYPE="STUDY">Cruickshank 2008</LINK>), as the mirtazapine study by <LINK REF="STD-Kongsakon-2005" TYPE="STUDY">Kongsakon 2005</LINK> met criteria for inclusion, but their data could not be included due to differences in study methodology. In summary, there are currently no available medications that have been demonstrated to be effective in the treatment of amphetamine withdrawal.<BR/>
<BR/>
</P>
<P>The high prevalence (about 87%) of amphetamine withdrawal in amphetamine users (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0005">Cantwell 1998</A>, <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003021/bibliography.html#CD003021-bbs2-0013">Schuckit 1999</A>) suggests that clinical trials of potential medications for the treatment of amphetamine withdrawal are needed. Additional clinical studies assessing the natural history of amphetamine withdrawal, the role these symptoms play in relapse to amphetamine use, as well as the validity and reliability of clinical measures to assess amphetamine withdrawal, are also needed. Medications that should be considered for evaluation in future clinical trials include those that increase dopamine, norepinephrine and/or serotonin activities of the brain. Naturalistic studies of amphetamine withdrawal symptoms and course are also crucial for the development of study designs appropriate for further treatment studies of amphetamine withdrawal.<BR/>
<BR/>
</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-01-05 19:29:32 +0100" MODIFIED_BY="Uyen H Kao">
<IMPLICATIONS_PRACTICE MODIFIED="2009-01-05 19:28:57 +0100" MODIFIED_BY="Uyen H Kao">
<P>The evidence about the treatment for amphetamine withdrawal is very limited. Although amineptine has limited benefits for amphetamine withdrawal, this drug has been withdrawn from the market.  Mirtazapine has not been shown to be effective for amphetamine withdrawal, although the number of studies is limited. At present, there is no evidence to guide selection of medications that might relieve symptoms of amphetamine withdrawal for patients in initial abstinence from chronic amphetamine use.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-01-05 19:29:32 +0100" MODIFIED_BY="Uyen H Kao">
<P>While there are few medications that have been evaluated, amphetamine withdrawal seems a reasonable target for developing a medication to aid individuals in instilling amphetamine abstinence. Chronic amphetamine abusers seeking treatment must successfully resolve amphetamine withdrawal when establishing sustained abstinence from the drug. It remains unknown whether improved outcomes in successfully resolving amphetamine withdrawal would also correspond with longer term abstinence outcomes.</P>
<P>There is good reason to consider medications for amphetamine withdrawal that demonstrate the propensities to increase central dopamine, norepinephrine and/or serotonin activities. Naturalistic studies of amphetamine withdrawal symptoms and course are also crucial for the development of study designs appropriate for further treatment studies of amphetamine withdrawal.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-02-11 19:42:15 +0100" MODIFIED_BY="Uyen H Kao">
<P>Dr. Robert Ali was the contact editor of this update. We wish to thank Dr. Linda Gowing for her guidance and support throughout the review process, Mr. Gregory Victorianne for his assistance in retrieving research articles, and Ms. Suzana Mitrova for her coordination assistance. We also want to thank Dr. Silvia Minozzi and other members of the Cochrane Drug and Alcohol Group for their invaluable comments on the review. </P>
<P>Special thanks to Drs. Manit Srisurapanont, Phunnapa Kittirattanapaiboon, and Ngamwong Jarusuraisin for developing and writing the original protocol and report for the review.  We also want to acknowledge Vanna Pistotti, Marica Ferri, and Meredith Cameron for all of their contributions on the earlier reports of this review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-05-08 18:31:11 +0100" MODIFIED_BY="Uyen H Kao">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-28 22:11:06 +0100" MODIFIED_BY="Uyen H Kao">
<P>Steven Shoptaw and Uyen Kao conducted the article searches, study selection, data extraction, data analysis, and write up of updated review. Keith Heinzerling provided feedback on the data analysis and assisted in writing the discussion section. Walter Ling provided overall guidance and assisted in writing the report.</P>
<P>*Manit Srisurapanont, Phunnapa Kittirattanapaiboon, and Ngamwong Jarusuraisin were involved in the protocol development and writing of the original review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-01-05 20:42:59 +0100" MODIFIED_BY="Uyen H Kao"/>
<PUBLIC_NOTES MODIFIED="2008-08-28 01:11:56 +0100" MODIFIED_BY="Uyen H Kao"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-02-16 12:07:35 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-22 01:37:27 +0100" MODIFIED_BY="Uyen H Kao">
<INCLUDED_STUDIES MODIFIED="2008-10-22 01:35:08 +0100" MODIFIED_BY="Uyen H Kao">
<STUDY DATA_SOURCE="MIX" ID="STD-Cruickshank-2008" MODIFIED="2008-05-20 19:49:17 +0100" MODIFIED_BY="Uyen H Kao" NAME="Cruickshank 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-05-08 17:58:53 +0100" MODIFIED_BY="Uyen H Kao" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruickshank CC, Montebello ME, Dyer KR, Quigley A, Blaszczyk J, Tomkins S, Shand D</AU>
<TI>A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal</TI>
<SO>Drug Alcohol Review</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>3</NO>
<PG>326-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jittiwutikan-1997" MODIFIED="2008-05-20 19:49:43 +0100" MODIFIED_BY="Uyen H Kao" NAME="Jittiwutikan 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jittiwutikan J, Srisurapanont M, Jarusuraisin N</AU>
<TI>Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>9</NO>
<PG>587-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kongsakon-2005" MODIFIED="2008-10-22 01:35:08 +0100" MODIFIED_BY="Uyen H Kao" NAME="Kongsakon 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-10-22 01:35:08 +0100" MODIFIED_BY="Uyen H Kao" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kongsakon R, Papadopoulos K, Saguansiritham R</AU>
<TI>Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>5</NO>
<PG>253-256</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Srisurapanont-1999b" MODIFIED="2008-08-28 21:14:51 +0100" MODIFIED_BY="Uyen H Kao" NAME="Srisurapanont 1999b" YEAR="1999b">
<REFERENCE MODIFIED="2008-08-28 21:14:51 +0100" MODIFIED_BY="Uyen H Kao" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Srisurapanont M, Jarusuraisin N, Jittiwutikan J</AU>
<TI>Amphetamine withdrawal: II. A placebo-controlled, randomised, double-blind study of amineptine treatment</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1999b</YR>
<VL>33</VL>
<PG>94-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-22 01:37:27 +0100" MODIFIED_BY="Uyen H Kao">
<STUDY DATA_SOURCE="PUB" ID="STD-Chan_x002d_Ob-2001" MODIFIED="2008-05-08 18:16:18 +0100" MODIFIED_BY="Uyen H Kao" NAME="Chan-Ob 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-08 18:16:18 +0100" MODIFIED_BY="Uyen H Kao" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan-Ob T, Kuntawongse N, Boonyanaruthee V</AU>
<TI>Bupropion for amphetamine withdrawal syndrome</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2001</YR>
<VL>84</VL>
<NO>12</NO>
<PG>1763-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cox-2004" MODIFIED="2008-05-20 19:47:07 +0100" MODIFIED_BY="Uyen H Kao" NAME="Cox 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-20 19:47:07 +0100" MODIFIED_BY="Uyen H Kao" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cox D, Bowers R, McBride A</AU>
<TI>Reboxetine may be helpful in the treatment of amphetamine withdrawal</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>1</NO>
<PG>100-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillin-1994" MODIFIED="2008-05-08 18:20:58 +0100" MODIFIED_BY="Uyen H Kao" NAME="Gillin 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-05-08 18:20:58 +0100" MODIFIED_BY="Uyen H Kao" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillin JC, Pulvirenti L, Withers N, Golshan S, Koob G</AU>
<TI>The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report</TI>
<SO>Biological Psychiatry</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>11</NO>
<PG>843-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGregor-2005" MODIFIED="2008-05-08 18:28:47 +0100" MODIFIED_BY="Uyen H Kao" NAME="McGregor 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-08 18:28:47 +0100" MODIFIED_BY="Uyen H Kao" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM</AU>
<TI>The nature, time course and severity of methamphetamine withdrawal</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>9</NO>
<PG>1320-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGregor-2008a" MODIFIED="2008-10-22 01:37:27 +0100" MODIFIED_BY="Uyen H Kao" NAME="McGregor 2008a" YEAR="2008">
<REFERENCE MODIFIED="2008-10-22 01:37:27 +0100" MODIFIED_BY="Uyen H Kao" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM</AU>
<TI>Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: A comparison of mirtazapine and modafinil with treatment as usual</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2008a</YR>
<VL>35</VL>
<PG>334-342</PG>
<MD>electronic publication</MD>
<IDENTIFIERS MODIFIED="2008-08-28 20:01:13 +0100" MODIFIED_BY="Uyen H Kao">
<IDENTIFIER MODIFIED="2008-08-28 20:01:13 +0100" MODIFIED_BY="Uyen H Kao" TYPE="PUBMED" VALUE="18329221 Epub March 6 2008"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-08-28 19:49:41 +0100" MODIFIED_BY="Uyen H Kao"/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-02-16 12:07:35 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-02-16 12:07:35 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cantwell-1998" MODIFIED="2008-05-20 22:38:19 +0100" MODIFIED_BY="Uyen H Kao" NAME="Cantwell 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cantwell B, McBride AJ</AU>
<TI>Self detoxification by amphetamine dependent patients: a pilot study</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1998</YR>
<VL>49</VL>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Boer-1996" MODIFIED="2008-05-20 22:39:41 +0100" MODIFIED_BY="Uyen H Kao" NAME="De Boer 1996" TYPE="JOURNAL_ARTICLE">
<AU>De Boer T</AU>
<TI>The pharmacologic profile of mirtazapine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<NO>(supple 4)</NO>
<PG>19-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Derogatis-1993" MODIFIED="2008-08-28 19:24:19 +0100" MODIFIED_BY="Uyen H Kao" NAME="Derogatis 1993" TYPE="BOOK">
<AU>Derogatis LR</AU>
<TI>Brief symptom inventory administration, scoring, and proedures manual</TI>
<SO>Brief symptom inventory administration, scoring, and procedures manual</SO>
<YR>1993</YR>
<PB>The Psychological Corporation, National Computer Systems, Inc.</PB>
<CY>Minneapolis</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM_x002d_IV_x002d_TR-2000" MODIFIED="2008-08-28 22:06:25 +0100" MODIFIED_BY="Uyen H Kao" NAME="DSM-IV-TR 2000" TYPE="BOOK">
<AU>DSM-IV-TR</AU>
<SO>Diagnositic and Statistical Manual of Mental Disorders</SO>
<YR>2000</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gossop-1982" MODIFIED="2008-05-20 23:07:44 +0100" MODIFIED_BY="Uyen H Kao" NAME="Gossop 1982" TYPE="JOURNAL_ARTICLE">
<AU>Gossop MR, Bradley BP, Brewis RK</AU>
<TI>Amphetamine withdrawal and sleep disturbance</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1982</YR>
<VL>10</VL>
<NO>2-3</NO>
<PG>177-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU assessment manual for psychopharmacology, revised</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<CY>Rockville, Maryland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-08-28 18:58:02 +0100" MODIFIED_BY="Uyen H Kao" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.0</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2008</YR>
<PG>Available from www.cochrane-handbook.org</PG>
<IDENTIFIERS MODIFIED="2008-08-28 18:57:43 +0100" MODIFIED_BY="Uyen H Kao"/>
</REFERENCE>
<REFERENCE ID="REF-Hofmann-1983" NAME="Hofmann 1983" TYPE="BOOK">
<AU>Hofmann FG</AU>
<SO>A handbook on drug and alcohol abuse: the biomedical aspects</SO>
<YR>1983</YR>
<EN>2nd</EN>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2008" MODIFIED="2009-01-05 19:24:54 +0100" MODIFIED_BY="Uyen H Kao" NAME="Lee 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lee NK, Rawson RA</AU>
<TI>A systematic review of cognitive and behavioural therapies for methamphetamine dependence</TI>
<SO>Drug Alcohol Rev</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>3</NO>
<PG>309-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGregor-2008b" MODIFIED="2008-08-28 21:15:27 +0100" MODIFIED_BY="Uyen H Kao" NAME="McGregor 2008b" TYPE="JOURNAL_ARTICLE">
<AU>McGregor C, Srisurapanont M, Mitchell A, Longo MC, Cahill S, White JM</AU>
<TI>Psychometric evaluation of the Amphetamine Cessation Symptom Assessment</TI>
<SO>Journal of  Substance Abuse Treatment</SO>
<YR>2008b</YR>
<VL>34</VL>
<NO>4</NO>
<PG>443-9</PG>
<IDENTIFIERS MODIFIED="2008-08-28 19:50:45 +0100" MODIFIED_BY="Uyen H Kao">
<IDENTIFIER MODIFIED="2008-08-28 19:50:45 +0100" MODIFIED_BY="Uyen H Kao" TYPE="PUBMED" VALUE="17629443 Epub 13 July 2007"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meredith-2005" MODIFIED="2008-05-20 23:07:05 +0100" MODIFIED_BY="Uyen H Kao" NAME="Meredith 2005" TYPE="JOURNAL_ARTICLE">
<AU>Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ</AU>
<TI>Implications of chronic methamphetamine use: a literature review</TI>
<SO>Harvard Review of Psychiatry</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>3</NO>
<PG>141-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newton-2004" MODIFIED="2008-05-20 23:09:52 +0100" MODIFIED_BY="Uyen H Kao" NAME="Newton 2004" TYPE="JOURNAL_ARTICLE">
<AU>Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W</AU>
<TI>Methamphetamine abstinence syndrome: preliminary findings</TI>
<SO>American Journal on Addictions</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>3</NO>
<PG>248-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pasic-2007" MODIFIED="2009-01-05 19:21:26 +0100" MODIFIED_BY="Uyen H Kao" NAME="Pasic 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pasic J, Russo JE, Ries RK, Roy-Byrne PP</AU>
<TI>Methamphetamine users in the psychiatric emergency services: A case-control study</TI>
<SO>Am J Drug Alcohol Abuse</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>5</NO>
<PG>675-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rawson-2002" MODIFIED="2008-08-28 22:01:42 +0100" MODIFIED_BY="Uyen H Kao" NAME="Rawson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rawson RA, Gonzales R, Brethen P</AU>
<TI>Treatment of methamphetamine use disorders: an update</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>2</NO>
<PG>145-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothman-2007" MODIFIED="2008-05-20 23:11:05 +0100" MODIFIED_BY="Uyen H Kao" NAME="Rothman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rothman RB, Blough BE, Baumann MH</AU>
<TI>Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions</TI>
<SO>American Association of Pharmaceutical Scientists Journal</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>1</NO>
<PG>E1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Samanin-1977" NAME="Samanin 1977" TYPE="JOURNAL_ARTICLE">
<AU>Samanin R, Jori A, Bernasconi S, Morpugo E, Garattini S</AU>
<TI>Biochemical and pharmacological studies on amineptine (S 1694) and (+)-amphetamine in the rat</TI>
<SO>Journal of Pharmacy and Pharmacology</SO>
<YR>1977</YR>
<VL>29</VL>
<PG>555-558</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schuckit-1999" NAME="Schuckit 1999" TYPE="JOURNAL_ARTICLE">
<AU>Schuckit MA, Daeppen J-B, Danko GP, et al</AU>
<TI>Clinical implications for four drugs of the DSM-IV distinction between substance dependence with and without a physiological component</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<PG>41-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scott-2007" MODIFIED="2008-05-20 23:12:25 +0100" MODIFIED_BY="Uyen H Kao" NAME="Scott 2007" TYPE="JOURNAL_ARTICLE">
<AU>Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I</AU>
<TI>Neurocognitive effects of methamphetamine: a critical review and meta-analysis</TI>
<SO>Neuropsychology Review</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>3</NO>
<PG>275-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-1999a" MODIFIED="2008-08-28 21:15:42 +0100" MODIFIED_BY="Uyen H Kao" NAME="Srisurapanont 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Srisurapanont M, Jarusuraisin N, Jittiwutikan J</AU>
<TI>Amphetamine withdrawal: I. reliability, validity and factor structure of a measure</TI>
<SO>Australian and New Zealand Journal of Psychaitry</SO>
<YR>1999a</YR>
<VL>33</VL>
<PG>89-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UNODC-2008" MODIFIED="2009-01-05 19:16:29 +0100" MODIFIED_BY="Uyen H Kao" NAME="UNODC 2008" TYPE="UNPUBLISHED">
<AU>United Nations Office on Drugs and Crime</AU>
<TI>World Drug Report 2008</TI>
<SO>www.unodc.org/documents/wdr/WDR_2008/WDR_2008_eng_web.pdf.</SO>
<YR>Accessed on 9-07-08</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Voris-1991" NAME="Voris 1991" TYPE="JOURNAL_ARTICLE">
<AU>Voris J, Elder I, Sebastian P</AU>
<TI>A simple test of cocaine craving and related responses</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>1991</YR>
<VL>47</VL>
<PG>320-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watson-1972" MODIFIED="2008-05-20 23:14:46 +0100" MODIFIED_BY="Uyen H Kao" NAME="Watson 1972" TYPE="JOURNAL_ARTICLE">
<AU>Watson R, Hartmann E, Schildkraut JJ</AU>
<TI>Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1972</YR>
<VL>129</VL>
<NO>3</NO>
<PG>263-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-08-28 19:24:19 +0100" MODIFIED_BY="Uyen H Kao">
<REFERENCE ID="REF-Srisurapanont-2001" MODIFIED="2008-05-20 23:17:32 +0100" MODIFIED_BY="Uyen H Kao" NAME="Srisurapanont 2001" TYPE="COCHRANE_REVIEW">
<AU>Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P</AU>
<TI>Treatment for amphetamine withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-05-20 23:17:32 +0100" MODIFIED_BY="Uyen H Kao">
<IDENTIFIER MODIFIED="2008-05-20 23:17:23 +0100" MODIFIED_BY="Uyen H Kao" TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-02-05 08:24:41 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-02-05 08:24:41 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-10-17 00:41:33 +0100" MODIFIED_BY="Uyen H Kao" STUDY_ID="STD-Cruickshank-2008">
<CHAR_METHODS MODIFIED="2008-10-17 00:30:03 +0100" MODIFIED_BY="Uyen H Kao">
<P>Randomised, double-blind, 14-day study. Recruited from two public inner-city drug and alcohol outpatient clinics.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-20 19:25:48 +0100" MODIFIED_BY="Uyen H Kao">
<P>31 (20 males, 11 females) who met DSM-IV criteria for amphetamine dependence; mean age = 31 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-20 19:25:56 +0100" MODIFIED_BY="Uyen H Kao">
<P>(1) mirtazapine 15 mg nocte for 2 days followed by 30 mg nocte for 12 days (n = 13) (2) placebo (n = 18).  Narrative therapy counseling was offered to both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-20 19:26:11 +0100" MODIFIED_BY="Uyen H Kao">
<P>Discontinuation rate, ACSA score, BSI-GSI score, Athens Insomnia Scale, DASS, Severity of Dependence scale, Opiate Treatment Index Drug Use subscale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-17 00:41:33 +0100" MODIFIED_BY="Uyen H Kao">
<P>Intent-to-treat analysis.</P>
<P>Country of origin: Australia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-17 00:42:30 +0100" MODIFIED_BY="Uyen H Kao" STUDY_ID="STD-Jittiwutikan-1997">
<CHAR_METHODS MODIFIED="2008-10-17 00:42:30 +0100" MODIFIED_BY="Uyen H Kao">
<P>Randomised, double-blind, 14-day study. Recruited from the inpatients of a drug dependence treatment center.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 (29 males, 1 females) who met DSM-IV criteria for amphetamine withdrawal; mean age = 18.5 years; mean duration of amphetamine use = 23.6 months; mean duration of amphetamine abstinence = 57.7 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-28 01:14:33 +0100" MODIFIED_BY="Uyen H Kao">
<P>(1) amineptine 300 mg/day (n = 15) (2) placebo (n = 15); trial medication was given in 1-3 capsules/day.  Dose titration done during first 5 days. Occasional use of lorazepam in patients with anxiety or insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-20 19:27:25 +0100" MODIFIED_BY="Uyen H Kao">
<P>Discontinuation rate, QECCRR score, CGI score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-17 00:41:50 +0100" MODIFIED_BY="Uyen H Kao">
<P>Used a last observation carried forward method for intent-to-treat analysis.</P>
<P>Country of origin: Thailand</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-17 00:43:44 +0100" MODIFIED_BY="Uyen H Kao" STUDY_ID="STD-Kongsakon-2005">
<CHAR_METHODS MODIFIED="2008-10-17 00:43:35 +0100" MODIFIED_BY="Uyen H Kao">
<P>Randomised, double-blind, 14-day study. Recruited from a probation center.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 males who met DSM-IV criteria for amphetamine dependence; mean age = 24.3 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-20 19:28:39 +0100" MODIFIED_BY="Uyen H Kao">
<P>(1) mirtazapine 15-60 mg/day with an initial dose of 15 mg (n = 9) (2) placebo (n = 11); dose titrations during the study was based on subjects clinical response to medication</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Discontinuation rate, AWQ score, MADRS score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-17 00:43:44 +0100" MODIFIED_BY="Uyen H Kao">
<P>Used a last observation carried forward method for intent-to-treat analysis.</P>
<P>Country of origin: Thailand</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-17 00:43:06 +0100" MODIFIED_BY="Uyen H Kao" STUDY_ID="STD-Srisurapanont-1999b">
<CHAR_METHODS MODIFIED="2008-10-17 00:42:41 +0100" MODIFIED_BY="Uyen H Kao">
<P>Randomised, double-blind, 14-day study. Recruited from the inpatients of a drug dependence treatment center.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-20 19:29:44 +0100" MODIFIED_BY="Uyen H Kao">
<P>44 (41 males, 3 females) who met DSM-IV criteria for amphetamine withdrawal and had AWQ score = 10 or more; mean age = 19.6 years; mean duration of amphetamine use = 23.5 months; mean duration of amphetamine abstinence = 52.7 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-20 19:29:59 +0100" MODIFIED_BY="Uyen H Kao">
<P>(1) amineptine 300 mg/day (n = 22) (2) placebo (n = 22); occasional use of lorazepam in patients with anxiety or insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-08 17:56:04 +0100" MODIFIED_BY="Uyen H Kao">
<P>Discontinuation rate, AWQ score, CGI score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-17 00:43:06 +0100" MODIFIED_BY="Uyen H Kao">
<P>Used a last observation carried forward method for intent-to-treat analysis.</P>
<P>Country of origin: Thailand</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Abbreviation: AWQ = Amphetamine Withdrawal Questionnaire, CGI = Clinical Global Impression, MADRS = Montgomery-Asberg Depression Rating Scale, ACSA=Amphetamine Cessation Symptoms Assessment, BSI-GSI = Brief Symptom Inventory Global Severity Index, DASS = Depression-Anxiety-Stress Scale, and QECCRR = Questionnaire for Evaluating Cocaine Craving and Related Responses</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-05-20 19:50:28 +0100" MODIFIED_BY="Uyen H Kao" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-05-08 18:30:08 +0100" MODIFIED_BY="Uyen H Kao" STUDY_ID="STD-Chan_x002d_Ob-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-08 18:30:08 +0100" MODIFIED_BY="Uyen H Kao">
<P>Excluded as study design were not in the inclusion criteria: not RCT, but a case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-20 19:50:28 +0100" MODIFIED_BY="Uyen H Kao" STUDY_ID="STD-Cox-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-20 19:50:28 +0100" MODIFIED_BY="Uyen H Kao">
<P>Excluded as study design were not in the inclusion criteria: not RCT, but an open label case series report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-08 18:29:45 +0100" MODIFIED_BY="Uyen H Kao" STUDY_ID="STD-Gillin-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-08 18:29:45 +0100" MODIFIED_BY="Uyen H Kao">
<P>Excluded for the type of participants not in the inclusion criteria: majority of the participants were cocaine dependent.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-08 18:30:11 +0100" MODIFIED_BY="Uyen H Kao" STUDY_ID="STD-McGregor-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-08 18:30:11 +0100" MODIFIED_BY="Uyen H Kao">
<P>Excluded as the objective and study design were not in the inclusion criteria: not RCT, but an observational study characterizing the natural history of methamphetamine withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-08 18:29:54 +0100" MODIFIED_BY="Uyen H Kao" STUDY_ID="STD-McGregor-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-08 18:29:54 +0100" MODIFIED_BY="Uyen H Kao">
<P>Excluded as the objective and study design were not in the inclusion criteria: not RCT, used historical comparison group and enrolled subjects sequentially rather than randomly allocated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-02-05 08:24:41 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-10-16 01:07:09 +0100" MODIFIED_BY="Uyen H Kao" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-15 00:48:04 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Cruickshank-2008">
<DESCRIPTION>
<P>"Randomisation was conducted independently by pharmacists at each site using the service of Randomization.com"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-15 00:57:36 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Jittiwutikan-1997">
<DESCRIPTION>
<P>"the investigators . . .randomly assigned either amineptine or placebo to the subjects."</P>
<P>"Block randomization was applied by the use of tossing-a-coin technique"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-16 00:38:13 +0100" MODIFIED_BY="Uyen H Kao" RESULT="UNKNOWN" STUDY_ID="STD-Kongsakon-2005">
<DESCRIPTION>
<P>"Twenty cases . . .were enrolled and randomized."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-16 01:07:09 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Srisurapanont-1999b">
<DESCRIPTION>
<P>"Blocked randomisation by using tossing-a-coin technique"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-10-17 00:18:17 +0100" MODIFIED_BY="Uyen H Kao" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-15 00:47:38 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Cruickshank-2008">
<DESCRIPTION>
<P>"Randomisation was conducted independently by pharmacists at each site using the service of Randomization.com"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-16 01:01:12 +0100" MODIFIED_BY="Uyen H Kao" RESULT="UNKNOWN" STUDY_ID="STD-Jittiwutikan-1997">
<DESCRIPTION>
<P>"the investigators . . .randomly assigned either amineptine or placebo to the subjects." </P>
<P>Method of allocation concealment not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-16 01:04:02 +0100" MODIFIED_BY="Uyen H Kao" RESULT="UNKNOWN" STUDY_ID="STD-Kongsakon-2005">
<DESCRIPTION>
<P>"Twenty cases . . .were enrolled and randomized." </P>
<P>Method of allocation concealment not specified. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-17 00:18:17 +0100" MODIFIED_BY="Uyen H Kao" RESULT="UNKNOWN" STUDY_ID="STD-Srisurapanont-1999b">
<DESCRIPTION>
<P>"Blocked randomisation by using tossing-a-coin technique"</P>
<P>Method of allocation concealment not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-10-17 00:24:14 +0100" MODIFIED_BY="Uyen H Kao" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-10-21 22:33:01 +0100" MODIFIED_BY="Uyen H Kao" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.02 CMP-001.03 CMP-001.04">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-10-21 22:23:19 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Cruickshank-2008">
<DESCRIPTION>
<P>Missing outcome data were similar across groups. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-10-21 22:28:47 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Jittiwutikan-1997">
<DESCRIPTION>
<P>Outcome analysis was conducted using a last observation carried forward method of intent-to-treat analysis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-10-21 22:32:43 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Kongsakon-2005">
<DESCRIPTION>
<P>Outcome analysis was conducted using a last observation carried forward method of intent-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-10-21 22:33:01 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Srisurapanont-1999b">
<DESCRIPTION>
<P>Outcome analysis was conducted using a last observation carried forward method of intent-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-10-21 22:33:04 +0100" MODIFIED_BY="Uyen H Kao" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-17 23:02:50 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Cruickshank-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-21 22:26:45 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Jittiwutikan-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-21 22:32:47 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Kongsakon-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-21 22:33:04 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Srisurapanont-1999b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2009-02-05 08:24:41 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding (subjective outcomes)?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1" REF_IDS="CMP-001.02 CMP-001.03 CMP-001.04">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2008-10-16 00:56:10 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Cruickshank-2008">
<DESCRIPTION>
<P>"Clinical staff, research staff and participants were blinded to the outcome of the randomisation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2008-10-17 00:34:20 +0100" MODIFIED_BY="Uyen H Kao" RESULT="UNKNOWN" STUDY_ID="STD-Jittiwutikan-1997">
<DESCRIPTION>
<P>"To blind the subjects and raters, the investigators filled either 100 mg of amineptine or placebo into an unmarked, identical capsule."</P>
<P>Unclear of investigators' role with study subjects or raters. Insufficient information to determined risk of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2009-02-05 08:24:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kongsakon-2005">
<DESCRIPTION>
<P>Blindness of participants, personnel, and assessors were not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2008-10-17 00:45:39 +0100" MODIFIED_BY="Uyen H Kao" RESULT="UNKNOWN" STUDY_ID="STD-Srisurapanont-1999b">
<DESCRIPTION>
<P>"To ensure blinding of the patients and raters, either 100 mg amineptine or placebo was enclosed within an unmarked, identical capsule."</P>
<P>Blindness of outcome assessor not specified. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2009-02-05 08:24:04 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding (objective outcomes)?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2008-10-17 00:23:06 +0100" MODIFIED_BY="Uyen H Kao" RESULT="YES" STUDY_ID="STD-Cruickshank-2008">
<DESCRIPTION>
<P>"Clinical staff, research staff and participants were blinded to the outcome of the randomisation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2009-02-04 21:59:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jittiwutikan-1997">
<DESCRIPTION>
<P>"To blind the subjects and raters, the investigators filled either 100 mg of amineptine or placebo into an unmarked, identical capsule."</P>
<P>Unclear of investigators' role with study subjects or raters. Insufficient information to determined risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2009-02-05 08:24:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kongsakon-2005">
<DESCRIPTION>
<P>Blindness of participants, personnel, and assessors were not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2009-02-04 21:58:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Srisurapanont-1999b">
<DESCRIPTION>
<P>"To ensure blinding of the patients and raters, either 100 mg amineptine or placebo was enclosed within an unmarked, identical capsule."</P>
<P>Blindness of outcome assessor not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-05-20 19:51:32 +0100" MODIFIED_BY="Uyen H Kao"/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-05-16 20:42:52 +0100" MODIFIED_BY="Uyen H Kao">
<COMPARISON ID="CMP-001" MODIFIED="2008-05-16 20:42:52 +0100" MODIFIED_BY="Uyen H Kao" NO="1">
<NAME>Any pharmacological treatment versus Placebo</NAME>
<DICH_OUTCOME CHI2="5.47350200903063" CI_END="0.9385329742180709" CI_START="0.28937211261671725" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.521138436032053" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" I2="45.1904832582439" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.02755046436454936" LOG_CI_START="-0.5385433250492302" LOG_EFFECT_SIZE="-0.2830468947068898" METHOD="MH" MODIFIED="2008-05-15 19:39:31 +0100" MODIFIED_BY="Uyen H Kao" NO="1" P_CHI2="0.14023219811357646" P_Q="0.0" P_Z="0.02990781627076523" Q="0.0" RANDOM="NO" SCALE="58.37" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="66" WEIGHT="100.0" Z="2.1713090817671232">
<NAME>Discontinuation rates</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3127944052494361" CI_END="0.6857681657768628" CI_START="0.06695902440283266" DF="1.0" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.1638226792507277" LOG_CI_START="-1.1741908826664238" LOG_EFFECT_SIZE="-0.6690067809585756" MODIFIED="2008-05-15 18:53:14 +0100" MODIFIED_BY="Uyen H Kao" NO="1" P_CHI2="0.5759705802534458" P_Z="0.009444042225758202" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="59.96131528046421" Z="2.5955472305226657">
<NAME>Amineptine</NAME>
<DICH_DATA CI_END="1.0236399778788619" CI_START="0.019936856420550257" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.01014723875593224" LOG_CI_START="-1.7003433187844461" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2008-05-15 18:53:08 +0100" MODIFIED_BY="Uyen H Kao" ORDER="15" O_E="0.0" SE="1.004750620564033" STUDY_ID="STD-Jittiwutikan-1997" TOTAL_1="15" TOTAL_2="15" VAR="1.0095238095238095" WEIGHT="29.980657640232106"/>
<DICH_DATA CI_END="1.225510044509201" CI_START="0.06661116604223115" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.08831687516136674" LOG_CI_START="-1.176452963861918" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2008-05-15 18:53:14 +0100" MODIFIED_BY="Uyen H Kao" ORDER="16" O_E="0.0" SE="0.7429320641539521" STUDY_ID="STD-Srisurapanont-1999b" TOTAL_1="22" TOTAL_2="22" VAR="0.551948051948052" WEIGHT="29.980657640232106"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.085970425318453" CI_END="1.9666162883340097" CI_START="0.48902577843473954" DF="1.0" EFFECT_SIZE="0.9806763285024154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.293719631848526" LOG_CI_START="-0.31066824693593575" LOG_EFFECT_SIZE="-0.008474307543704873" MODIFIED="2008-05-15 18:53:35 +0100" MODIFIED_BY="Uyen H Kao" NO="2" P_CHI2="0.7693638420600923" P_Z="0.9561683308749238" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="29" WEIGHT="40.03868471953578" Z="0.05496251054201206">
<NAME>Mirtazapine</NAME>
<DICH_DATA CI_END="1.9484979891042913" CI_START="0.4372963229532764" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.28969996192683045" LOG_CI_START="-0.3592241744452543" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2008-05-15 18:53:26 +0100" MODIFIED_BY="Uyen H Kao" ORDER="14" O_E="0.0" SE="0.38118124993124375" STUDY_ID="STD-Cruickshank-2008" TOTAL_1="13" TOTAL_2="18" VAR="0.1452991452991453" WEIGHT="32.32937275490467"/>
<DICH_DATA CI_END="7.03924511695163" CI_START="0.21221411325718045" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8475260882443147" LOG_CI_START="-0.6732257368065142" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2008-05-15 18:53:35 +0100" MODIFIED_BY="Uyen H Kao" ORDER="13" O_E="0.0" SE="0.8932971498777984" STUDY_ID="STD-Kongsakon-2005" TOTAL_1="9" TOTAL_2="11" VAR="0.7979797979797979" WEIGHT="7.709311964631113"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.536601961222771" CI_END="-0.006371850386184819" CI_START="-0.5423509714574298" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2743614109218073" ESTIMABLE="YES" I2="69.40306275547074" I2_Q="84.68125606798817" ID="CMP-001.02" MODIFIED="2008-05-16 19:49:26 +0100" MODIFIED_BY="Uyen H Kao" NO="2" P_CHI2="0.03807112788707612" P_Q="0.010619255643706693" P_Z="0.04479599656535029" Q="6.527950362237492" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="54" UNITS="" WEIGHT="99.99999999999999" Z="2.0065650433530893">
<NAME>Average score in global state</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.008651598985278565" CI_END="-0.17317952682937449" CI_START="-0.8005161166598291" DF="1.0" EFFECT_SIZE="-0.4868478217446018" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2008-05-15 18:59:14 +0100" MODIFIED_BY="Uyen H Kao" NO="1" P_CHI2="0.9258924617578204" P_Z="0.0023494906902185838" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="72.99523428155791" Z="3.0420804781340145">
<NAME>Amineptine</NAME>
<CONT_DATA CI_END="0.0037316569928180776" CI_START="-0.943731656992818" EFFECT_SIZE="-0.47" ESTIMABLE="YES" MEAN_1="1.53" MEAN_2="2.0" MODIFIED="2008-05-15 18:58:54 +0100" MODIFIED_BY="Uyen H Kao" ORDER="19" SD_1="0.64" SD_2="0.66" SE="0.2417042663689501" STUDY_ID="STD-Jittiwutikan-1997" TOTAL_1="15" TOTAL_2="14" WEIGHT="32.0015444355201"/>
<CONT_DATA CI_END="-0.08143841099276394" CI_START="-0.9185615890072361" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="2.1" MODIFIED="2008-05-15 18:59:14 +0100" MODIFIED_BY="Uyen H Kao" ORDER="20" SD_1="0.7" SD_2="0.7" SE="0.21355575526325812" STUDY_ID="STD-Srisurapanont-1999b" TOTAL_1="21" TOTAL_2="22" WEIGHT="40.99368984603781"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.4510380936949446E-32" CI_END="0.815700639058144" CI_START="-0.2157006390581438" DF="0.0" EFFECT_SIZE="0.3000000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.02" MODIFIED="2008-05-15 19:00:36 +0100" MODIFIED_BY="Uyen H Kao" NO="2" P_CHI2="0.0" P_Z="0.2542132426763273" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="18" WEIGHT="27.004765718442073" Z="1.1401754250991383">
<NAME>Mirtazapine</NAME>
<CONT_DATA CI_END="0.8157006390581439" CI_START="-0.21570063905814385" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="0.8" MODIFIED="2008-05-15 19:00:36 +0100" MODIFIED_BY="Uyen H Kao" ORDER="18" SD_1="0.8" SD_2="0.6" SE="0.2631174057921088" STUDY_ID="STD-Cruickshank-2008" TOTAL_1="13" TOTAL_2="18" WEIGHT="27.004765718442073"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8337015188082855" CI_END="0.37836868938315793" CI_START="-0.5414661716722642" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08154874114455313" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2008-05-16 20:42:52 +0100" MODIFIED_BY="Uyen H Kao" NO="3" P_CHI2="0.36120444514324346" P_Q="0.36120444514324346" P_Z="0.728197282859456" Q="0.8337015188082855" RANDOM="YES" SCALE="1.66" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="40" UNITS="" WEIGHT="100.0" Z="0.3475245446655746">
<NAME>Average score in withdrawal symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3391497887147576" CI_START="-0.8623553258015775" DF="0.0" EFFECT_SIZE="-0.26160276854340997" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" MODIFIED="2008-05-15 19:17:06 +0100" MODIFIED_BY="Uyen H Kao" NO="1" P_CHI2="1.0" P_Z="0.39339160298177933" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="58.609562874755014" Z="0.8534828498128386">
<NAME>Amineptine</NAME>
<CONT_DATA CI_END="0.3391497887147576" CI_START="-0.8623553258015775" EFFECT_SIZE="-0.26160276854340997" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="9.5" MODIFIED="2008-05-15 19:17:06 +0100" MODIFIED_BY="Uyen H Kao" ORDER="21" SD_1="5.6" SD_2="4.9" SE="0.3065120389950158" STUDY_ID="STD-Srisurapanont-1999b" TOTAL_1="21" TOTAL_2="22" WEIGHT="58.609562874755014"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8882854175865506" CI_START="-0.5414637701136898" DF="0.0" EFFECT_SIZE="0.17341082373643033" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" MODIFIED="2008-05-15 19:17:43 +0100" MODIFIED_BY="Uyen H Kao" NO="2" P_CHI2="1.0" P_Z="0.6344743958452682" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="18" WEIGHT="41.39043712524498" Z="0.4754385901761193">
<NAME>Mirtazapine</NAME>
<CONT_DATA CI_END="0.8882854175865506" CI_START="-0.5414637701136898" EFFECT_SIZE="0.17341082373643033" ESTIMABLE="YES" MEAN_1="23.7" MEAN_2="20.4" MODIFIED="2008-05-15 19:17:43 +0100" MODIFIED_BY="Uyen H Kao" ORDER="22" SD_1="17.7" SD_2="19.1" SE="0.36473863779587773" STUDY_ID="STD-Cruickshank-2008" TOTAL_1="13" TOTAL_2="18" WEIGHT="41.39043712524498"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.094381993085662" CI_START="-1.2343819930856554" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.43000000000000327" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-05-15 19:45:08 +0100" MODIFIED_BY="Uyen H Kao" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6126005578483978" Q="0.0" RANDOM="NO" SCALE="2.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.5063648350279016">
<NAME>Average score in craving</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.094381993085662" CI_START="-1.2343819930856554" EFFECT_SIZE="0.43000000000000327" ESTIMABLE="YES" MEAN_1="18.67" MEAN_2="18.24" MODIFIED="2008-05-15 19:28:36 +0100" MODIFIED_BY="Uyen H Kao" ORDER="23" SD_1="1.7" SD_2="2.72" SE="0.8491900903353793" STUDY_ID="STD-Jittiwutikan-1997" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-02-05 08:24:42 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.JPG" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2008-10-21 22:10:24 +0100" MODIFIED_BY="Uyen H Kao" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart showing identification of trials</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-02-05 08:24:42 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-02-05 08:24:42 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUEAAAFiCAIAAADnVP3+AAAQPUlEQVR42u3dsY4kRRLG8ZZwMNZY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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-10-17 22:52:42 +0100" MODIFIED_BY="Uyen H Kao" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Any pharmacological treatment versus Placebo, outcome: 1.1 Discontinuation rates.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArUAAAFwCAMAAACRs3PpAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2008-10-17 22:52:35 +0100" MODIFIED_BY="Uyen H Kao" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Any pharmacological treatment versus Placebo, outcome: 1.2 Average score in global state.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAAEwCAMAAADW9KRAAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAgRElEQVR42u1dTawlx1WumXlv6jnYZOJ5Y8/Eo4TEUhAoECksEFLE
zohIBYqIBEhsYZ8tYsuCrJBYsEAQiewjFlRWWbGBLJIIi0QBO3ZsxjAznnlinDiZV34zfrzb3fX/
3//33u+z53Xf7qpT1dVfnT5VffrUJUoAYB9wGU0AgOoAAKoDwLbhYAvqyJq/PHiKp/LxccrmGcGM
8OlbgMu/iTbibV026VJp97Sa20B1HiUTy/eQoTfvonC3y7C1ttJFRRWN+Hpv5kLVvLQVMzCs0xat
LlA/uj9ctZpM0h4crjHUrfAEm5WZRavbRVoVMlqIM0tB+H+50U5kjCbanmpula3Om1bY/GF8s+Ft
E7BWUzB5sj3CR7yNIcG6MjN3en39XYVctblJQozamTU122nC6q+xmgdkK2FdO/d6PZ+u3KUuuLNs
3evnfS+A7101t4/qTKoNNpF9vs3XH28NRuZtrvVVc/uozlOTHnzXKZ65/nhr8Jmaa73V3MZ5dcb6
nuxlJzG2JdcfIJaZ1M7W/Zrw4tZWzW2j+mYESni7cUx2dTJkz49QHA9YoGy26TLeFmRfv0MKTmKt
4V2Af1U7X81LcPcC9gNwDABAdQAA1QEAVAcAUB0AQHUAmBrm21LlTGxNYqbmNGWOfMoK5L2eI9Ww
a6NOGBUMV3X+ArkulLvn5V7M2175+amETZHBxjelKifBzkuc2adGuXlrrptJ9dZvknFWcWVtjoW7
q66G61xutxJbcYE82JsiaRnjVufhJNdNtd89l4TyT42BFdftwGvyzatw5QHOlOppa285I6tr0V72
2h/Z8+hmyrW8gEucuf3d9HpOcIUHW0Y6UjMecX6euUBdnN9CRDpJ1d1iw22fEfuJEXxCM/NxwifX
RSuom2Wrdy/bLZOEOdVRvsU6h/VkZjpTwKObVb2tz3s9k2A1wnJaJcxTzs9zFtgd1S2k2m2gt712
82ahii/q0bNk3S7basovrHOfD6o3LwePPY5J7oSXilukYKncnJT7A/FgytkLTDYPL5BpG0qMqaIy
boJtv2LTEWu9dTvwjZfK6yJT2uplXs811cjImr1AMopTmjSm5KAwYEKbRldjQvFZ9Pt66nYQeqjW
kn0qipd7PRdXI/dB9iwF8tZjr9NzfMxWYxGJfOnPVpav2+Wo/cny0z1GDmYRhsXVZXUTsaokw+el
Zi/QkMcqFAwP3DE1LGBMiuv2mG1LMdsjeUx7YbV1u2xblZ1/sJza5M5T2rG4jBxcP6W4XVk/QUlz
ZbyePXOYSQOax+xldWFsDQUGmtRu7P6PS7fN5THu3L8FnO4XrVuZv3pVeYzHMrBd/iBuuG7n1S1U
MlxY6rXH6up2UET0qhvAxw4vsieobzcwfXytDgAAAPTDl2cu7wBaHVgIM1MPTrzAngBUB/YE9gyM
6Wbs+k/7EzHRmTHGMa8IrJrqzOCw9E1N+U1HjmOyEVg51VmAw+arf96Gdjad2e1I2MpRnXHvHACs
yFbnRapbhTPXxkoksDmbOIo3APSjOg/Y4REvdR7pCjOFOQeAgcPS/IiTJOzzPucAYFGqBz/9S36O
kOoZUO7A2mz1ltPqgynH+5TzJGeb1CxxDgDWRfWOm1XsVH7F0mE9dA4AlsSono2gNFDBlpnJAscA
YK+HpT0BnQ5sna0OAKA6AIDqAACqAwCoDgBz4ABNAIyIs3ZzuH6qC2r97yJ6Qp3e/G0/kG03YnOk
72sqVZAgUpgtSh9Qe4LmJYrSOuULFBlJsjqhanki1AGaug6zSGE1sZBtkGyW8DUIsusf1PtanXo7
4dPBeyBbn8oNVcd7MN0pVbgM0AfUniiSSMu7WrpAQdOdS/iX4goLyRQ0wXSjSMVyYV5Xulki10AF
2TuqXzTzpmU2rS1bRe4JfQ82TdRqWqp0SaS1RE91oeV1EjJyaKnE4gqVFUhLLqFX9vrH35Qocor6
p4q0K7DVacxI0brG0EYqMR35NtCEIRHSnzTHLULLxZU8cyyjIV1grc4sazQpNptajKGz+chp2Qqo
blJbKnf/TtC46hPxp3Zv1gua5FVqCBEVN4RzurP3V6kiOL7YPCbFaLbzztsl087AiFQjtndKbsZi
utyJ8apkTFpu6ZQLoUP6S+zhGeu6ztMoNG9gp+hugkAIN5vqNVpR6rQ8CeZt5rHvq6AzVCv01BQl
fVR4I2cazjEf3Q/XS/X0K6SN7aIGooUPx9GtlwqRlNKS0encTA9XSwwezGSvVtQ0yx5pdSpMVRyy
H/Vtoc3sVFD3dGKoGMlSaHpbWCSVk0B1pRUnFgGDwC5wyFVKYd28tnER7T5NZ6NZwW6zdLMHY17D
NgHx1XcImeeDoAMyjw98hQQsMt2y+zM18IHZIQx5x7b7T3dodWBPAKoDewIYMMBYOJM765xch1YH
9lGrG37cA6eebDdt2zFbVDmhENttnUZmD4zXXGmfWpq/OmH6aZExCoxWnIauL+GvbvmaWy78UV/1
Qp/7/fJXF5SUOsyWklTJtb2jqjqSMOsX/MRBHc94rCtnzGzPir8h7lNgtOLB60v4q5uCXBf+iK96
qc/9PvqrG67qSv3K1rdd1OO/hOw2IknhKk9VUtYFRd6nNuPSSiNF9y+Qll9f9ZMuh1E9ggqNYTFj
nQZQnRLvExbVuLaLeuIXTXqwW/Kq7lW+d5SIrHH2HY9zMZLTflKXeJtPC4el6zSFTKqrlg96ynku
6mGHdZrSB+aG9uHG4NfXgpJp+RsRVSGxzF+9xAwURVezLz4wB2GNHmkCUfM8c+7dCI7su3VDogwM
+qu7jmdZPR9o5zCnqwdPuzIsTSkOe0iXH+CFTVa6BH2mUuqFBQaTxb3IA/Y7rVYE/izSfrv2XS4Z
hAjnoKjT6yK0WcS/aFXmyyAvclGcYj6FfSixfq3ujJK0O7PUMXK3nXOxn5COuWM2sO0XLRPSupnc
hFM6LZ2pF0WDOe1AnrFuiwssKbfIXz3va+6l8K4G/upTTHQBq3lgCbq6uwp/dWAqk2bK7Ns2A7OX
EyE7gqHxoEa5qaff+9IpOXzm/tmuGDAAEBiUvnD2wf3NzvUT8uLVqz86ggED7B5Ob7/wFfrmnYbp
5ISQ+3fe+L3nb/7HerV6E1mM61/c7XwsdJK1mdrMrFmnlBsCNwk4W8eCYF1VCZtrhbJ0gW0kN9WC
RoOZjehLUzdAHWC2AGPPzBMU0lViQJN894tPzh4Gz/zKe/TB2Rq1OmvWm2bB++Hu6iObXB3PN6tV
c2IL7DKxdTC9rQ8LXOYSBfJ2fW/dTHKPJ6Wp9jQPcCdJt2cmCQvpKtGTdu/d+thzn71z97z7ed3e
/lD8+P1rN/71dJ3DUi77encTmNbczFTixGxhYq3OK3trc4grpbE8uK/Xli6wXbx7GZXHAveuyjg/
/kC8dNLY5ifXo9v75HdObh4e/ffyt9+y1Z3F1ln7GOWdKmh3Tc3P7MyspF2X1etdF2ZsVQVWr0w/
TkcYIOS9l45/8f23/vfkpLXNM//u3Xn9ua/c+uR6qM5dsvNg88TuWvesnpVJ1Te3eyrxubpepsCO
4u7pERqR5/sPH6DUf/0pOa/KcH7nnKyH6qSzHLP2Z4j7nEvzk3GsSj20f2QasVPqcbVDfCN9XLx9
7+FPj37p1nFnl6f/Hb947eWH37j39qpsdV7NdD37AvQZtpbb1dxV+9xu+vwcSmweqKdmOr9LTn/w
haN7G5t8Y6eEtzeuvnz/jLxztHxrHwSvmZVbhN3gU2XWmThjvH9DLsqsWQtkcsKQx21x7uhrPXfA
w0lCRfDRm+KCwI/Pn/nkH3+VdHa5vWXfu/rwJ6u5/aF59WbipftfT74au92Z9pYwNXXcbrk7y8vC
s8SLcD0817xUgYrkqpkCjehKU5Nj1nQ6d5NYRTtazBHCB5P/8EVx/VX70PEB/eZvzDC27kf16fQk
g/m+7OMjT6vBt+j0e79/9rTT6DcPHj5enWPAQB+YwuoyMH3qpwcfyvQxtNHhC6dnv/nvBw/P1kgK
uHsBS/VPuHsBAKgOAKA6AIDqAACqA6A6AOww1d311Ks/Ihd+HiHMIEli8zuSxNjz468RP5exJwJS
A3KbjRW+KV6b5q8AP3YIoy4QE1hx2V0X3A9+58X7Dq57TeNMp26wyYhcGUfcDrkark0ixjmwUwZM
p/+EVHLG7kbfCWKc0AqzSabTS/pRS00KURc32pIXp35dR9SR+EDn/dbqWv/ZMdSlvjM1sBVcfbMg
u/AUvBlZVpiKm+afDd36BUIvT+FEbvfi1ZLcAp1Ch0pM1ga9YIepLspMEzNMLA1RKUASJxh7DYtU
cTQ1SCDJxQvkGIAGaxW6iJIY58DWUp2qQWCe/f1CrU+EbKx82q1eULWuyggrFwBrH5bSPIloOdcC
fCkwNEifTOEktI9gQTEBsx8zMJqf0dkPf50BZQybuyHN2GuFu77LHGXXaIHq3luqy4jb7RJ/1Dqo
l3nxQ7H7vCqI3e3F+7YIml1OJjolGIsjnl4PJR/jHNhS9PJXHxzLe4RCepe2L0v/rB5z+6tXv0IS
2Qf+zDyqfNMDlsOAGWWyY0TLl46eUKcG3fcQcPcCQHUAANUBAFQHgNUPS0VwlCfnyWsXGXXdsNxJ
akGtYv0V3qmzpzPIt/wkk8fcYOIFVNe7qfnmgUxJeZMU+Zqbfrd1/ukhN3UABkxHGuujHcdfXbmi
y096gk7ttizRObkbX/gI0wdd1Dqt1AAUB1yt7qhHUxs6ruvEfufoO7U7sqjl1d78b3qNpywZYlst
PfzTJeOh1kH1So1Ibf5Yn9OVqlAaso5c4z5lEJGqd0FgORCmeqcqRTFzRXDX/y3KiegY96LCZxgA
SqlO88PUmJL2voKm5QxNGzDhyhQZMFDqQNyAKf0Ahwrq0kkkmaYtfe80TZCTRpU/zBegN9Vt927F
lKiHOrGd2i33ciuT4fHeDjSpntGhoSp4Puykj386JtaBDbYvvnpPzoLqawPiq+dtJjAd2Auq95t+
AdNBdTQBAKoDAKgOAKA6AIDqAACqAwCoDgCgOgCA6gAAqgOgOgCA6gAAqgMAqA4AoDoAgOoAAKoD
AKgOAEnYEQMY4d2WuHus2W7+ykSZ72BVMgBYnVZnmqW8/aH3NDi3U0fAwXRgrVpdcVeT1KIr45L+
TKn1Vuszoja8PS83rHsWQMUDa9LqFXTkG6V9wWfeaP3ml/yhuoDcCz0aAGBBqvOgpa32eKAzXFCY
qVTqB+/TeQBgPq2eZHoyYbuJpmXQ6cCabPUs01kiYbJXQLkDK9TqjClVzUpnDJ1kDHod2BKtHppY
38yoW4Tm7GIcKim8mXBXP7hN/eY4FDuwLCaIxIt3R0ARTxCJFwBmNGCGADod2I5hKQCA6gAAqgMA
qA4AoDoAgOoAMC7syUZ/rXW1MlxqHXT3oFzxNLTpAUNwWIIWnSukWyE4nSovbpwC5bqqRJ5VLZVc
CNwrXOj8NJMiflasZGW0s+bv4dRUF34T057U7Jaz9jZ9xAX2SLjauUIEKUiVFzdOgd1R6iZr/k8w
3S3ckE6zKaJn+62Rua1avWkA2rW02Q5Er64uVYIwtIWgZoqxF04U6iaIobejEzCy+qIldU/m67mo
Ki1NQQeKGeMu+oe+kbCoxXhtEDFgZGbXWlFaQKoEqXws1TDNQrh0vHtCJ7mHdGiBgVbbuRWFA9cT
9oE5m+xOHRRVzOKxVtzUSZ4yqqmYQX+UFlJomBaIU728l5xg1s0zUpRVsSCRoNGSdLX2Yq3uch8Y
EbhpIveQSo4DJlCxhYXQsqoUiKNjVst+rgpafx1V+mSWW7Jmqscuvm1W6upuEWp4gXXOyy2XoP3S
c1RCK5T6Os2lw8kkX3YeaOZlB6Y+RMFwY/VMF6ti+qTXsXVMn0urm+ZJazHKvW6H2gaMTqMOtPMy
Taourb2ZghdUTgQVFpJJlRc3ToHCMjdMYe0+LayeJ12nEHLOXOhnrpdfEEHIHrD9EkyNXTOIep6e
XbfjKyRgEdNs598ggeq7BDpgtoiu4fF+evvWjS8/+9y142cuffIUBgywIzANmO//2q2z3/7Wg2b/
+kl77Obln3/swU+PQHVgN6j++CMvPv2Trz2IJbp+5fDy33zxo2NTvYunq35xt/Ox0MkuUEybmbUx
Sw2BbUjetXxaPXtg4GSBRhhjFcS+PcBjgzYvQI8TAD+ZJHF2gUg9H/2FP/3bp08eFqW9cfD4+Suv
DdPwl627EoiYy4K7+ogOs9sF57UFEhbJuhDTCZk1MHCywO445zpiPc+Qzot8b8rm+STRs3Py/PQT
H3/h+Nqz7/74L07vtUy/LnV4bPvg7qM3Xz++9vzxrdu9bXj3bSlvFZEKN8q05mamEidm6xIrzhHj
xqF2n7P1MH3Ou5q+bE4CrRcwZDOZc0n4UDnj4fDW2dMnL1xq7fGLfyeVW3L9f8ilFy4fXrn6X/Ua
3l41g7nNzXhngqhdbqkIKzPrfdPnAlfXyWctcJp+tE1h1A6/c+vG86+8//pbd+6+evHzZMC/d+/d
eeu141euHd/8zmFPqnOX7Dx472KMbrsAy5J+eabPZ8Bw3WY8bsp7Sr2sEUuuwooJHriT0bOj443z
S+d3xhN38m1C3vtSb63eLn1R1ngu9ztz80LnM474XjEDO9eYZORGTHFZ1WoWpp/90b13/+8/z1/+
1O2XblxvbPDe/y7s9U8dnf/00cPH75z1t9V5NdP17AswKhP7jg14rfw5zaDWwD795Q+efuTp/Y0N
vtHP5dsbl29fuS/OtKTeMzDMsayLGMyYbdbo8VRr0KyvG6ymSjbJzGrlBqWbyPcs/Dwwk1hMtzLo
HwsY/Edv33188oheefnrt28et/Y3Ient8ce//unnz3/y6MG987O+xYbm1dXadExPyBBzVwVQZ1xp
Ejkzw7g7w8vis8TLsGst8+pMaQRpsIca0c/D7XtCHN1trDNozH6pW+YIsCsx671oCvz+7z558lv/
En2FRF688mf/+M1fHeOd6bC3paXtg5Drcz8jotRazy0y63P4bfb07OkD6ROw2R5fPrhy9Qd0PMeA
K4OiTr/2mdeK0n0GTJ8cnyHpm5FjOnlt7gobBX74d+//7FQ8+fuv/dtzz3zi/BcP/vyt40c/f/yz
n/zVX45XHnxggKUeQ/BXBwBQHQBAdQAA1QEAVAdAdQDYYaoL46+9VwgRDm1XJFH4Z0XPagDA1Fo9
FNZnUHYAmJjqQogu6lOzZ+5ebBoCqxOCmL+ITt+wV3gS3bxSBOnE6gREnVEHAKAvgn4Bch0FL4J6
F1adkEig9U0kOxHS0Fqil9cKOpuI246Qp8B4VBdltgUVKaODWqubhFY6ccKyU+8shUUDTEt1qsyI
PPtLQ6uHuJ41RkR1DgDoY8CULMoyYHUwJyx7SQLod2CaYWlasYu0Ynf0eDAqvjByiJB04Z2BYgfG
1+oyYrcVT11H82723EDrxF4wQzgnhbGemAzL3sUQN0OJt/tOgpkWUgJ2G5f6Lkza/7STDDMre4q5
/dWrP0ISWcsZ3AW2Z1iaAB0hhZUOHQNYdlgKAKA6AIDqAACqA8BahqUiOEyUU4JVw0dv2XDhLcSp
PbyCg1N7yWs7Q/tSyl94Wc/td5P4JOyXAOw71VPegwMJ41GfWMX6J/13tcKsSiiP9n7UfpbgOpA0
YIThNN45pzuu6/osCTu127JE5+SuPd5b1/ZoR/J1eg3oKN0T2F2t7qhH08XccV0ntge573/uyKKW
G3rz/+YQDWlyahsnjtVCPMMoaMuYdgzUOhCjuq8fo8cc3/Ti90E0pMMrGCn8PhF4LOB7DiBD9U5V
lrtYieCu/1v0HgeIHj7DYDmQozrND1NjpPI8zWk5+XLGSKgykTxQ5kCpAZOaMiG2BeMNJJO805a+
d5qmO5PIWVOpQgDgIERf6ZhuTepFPdSJ7dRufYphZTI83tuBJtUzOrTUtImOMjvpzWfeza4+AADb
GF+9lrqg+kqB+Op5mwlMB/aC6pUzK2A6sLVUBwBQHQBAdQBUBwBQHQBAdQAA1QEAVAcAUB0AQHUA
ANUBAFQHAFAdANUBAFQHgO3GAZoAmBCfeEA/PLr6DrQ6sNP47o1rrz+6/+GdN145/vjh4rW5hK90
gGmYdfzBu8ZP9h16cmYlWHAtJNb85X5NWHfw4ghrUzRJOdvsq2TtqYu0c19CDZisPZ+puK4o5hZo
VkTXR7ah2a62NCedEm+dSBXtCulSsFGb5PTlx08e2FbLRvrnTuiPjtZgwHDe/jOJ7zQS2yRoG7FJ
bd872fhsxUy3azo9mnbySzMrousj93ism9rpONe3ixPv0oJF+4XpTjESDl96/sabdx9sdq93h7rt
q4/fuHH9paVMmYMwHzYaWytxqzltRSGVT3Oo3efrpfoSz5Bol0tnTXGPl5TAa7r/eDy/8Yf/8OYF
t0+afyfe9iEhx88eXX17FcPStrfz9iFqKAmrSRhjs7XeiNSb3bRq28kvly9XNJmuLu/d+hj98Vcv
2ExOEv8e3nvrtWs3v7uuGZgLnrPYc7m1Z3Kk33dETCWeV7SZdmXhIUC+6AmZTt54+oWTwqQf/sEa
DBi7Qa3m4sw07DYjqotB6NZQnXHzIuYger+HSUG7Zu2TnkUPw+fJPz97/YO7yn6J/Lt19eTROmz1
VIPyNQ86i8zSi5s/+0WwwaRj3hyAd3/Cw1lmjaemN5zO7pHXXxF3N7bKxjb3ttfp1W9/djXD0hz3
uW5iff8uVCWvGAstY03IeTU+02Rj1x68aJRoJmE8bmU0T1qeNER0EvOSnRSTXfUFk88/LT7PpS2j
t+zVwzeOyEJMD1C9eb7zhrvWo76ZRmctT5ihIJiVba5B1xDGs7m6pNVOJNHSXapQu4alRV4NRERV
pRgDR4T89Q8fC8twf/Hqg281Z5ZCxdvSUoKsXLfvIrJNzvgSd+32B59rhR4fBOYXF3xbmtdRdaMx
YP4h9wCmT4B3yLeObpySw6N3z1bQRPCBAVbZO8cHPBuBPQGoDoDqAACqA8DWAcNSII/yBaUqlp6a
QmgqJbQ6sCc48LqEsdgure/8bh578VPRLE8XTtLukcDquu0S1zSSqRMaWJLalEsDFUzVRm2w8uku
Un0waPCBYjCFEuotV20mMSiffjAZmTYbmkyi9hpmm+mitdEbQcH0XaZ6o9NEu7Jzq9fU7kbRtWq2
O2Eowc0vodJL+slVp+VS0TTWR4KcavO55wayT0lL1GavbfPsgfKsYyQdkJKmqd7qNKq1m6PoDE0p
VZ+mtfDoQg3TQUh7xFLi1LF2hGUT6d4SIKJj66S42hksgmrbJ1WbvmbcDoDu4rD0oKzzWBLM9aB9
0TT4yKf2lgYt/LBdrIqLU1DZ3LTXLQ3Wpu0WRD6ogJ0yYNQtFnn2i76PrXg3or3VKB1PN1DZvdSY
NTDYBnbGVqd5ElXYzgGipA2NqNme7RC95IZyUdvqAXZ4BiYx5yjCZjLVFgwxd0XpyC9ixohQpoie
pWl9XZwLarznQJ0uK5TWUp2q8SHVk9PdbvdoN04Q65ewZlPsZCRR2GawaCVuJUhLwuttMm10LjAl
N85kfZVqhp/CVi/r+4EXJEWpRxOZrmYvx4DMdY+jEkul1JYm8FKox80opJmgpfek6DbUicxUs9ox
QFxgDqaXP7PEJD0I6N9oE7RxGdNpL1u9v9000nXS0RPq1KD7VLZ6hXEyvkhKRqU6AJR0jbE1+3CR
oDow5uhxzOf6yKYCqA4M59hWGITwVwemeBKsUKQx2SiCPVTO9VT1XO9duvBmpw3nwlCpnq+5cN9f
1vunAwOoVjyvrt1eR7OMSkXWzKuL2HvD+tkmQVPUJ95576Ttay6MLzE6H8kS/3TMoQMpA0YIoTai
c/8S8rDo1HB3ljhnury2rIsz5kkpV0R7GO2jVACgclhq+adT9XWF4aFO7JddvlO7I4taXu3N/6bX
eMqS8bjfyz8dADIzMDRzzPZNp8VD8aDnecUXEX390wFQPaRey195ifhIWeSH0cv6pwP7THX9bU4h
Wxy3wSgpaUGHqfs+o59/OpBE5eqOwTCjqdijjPcvLF+BaMkHZVMoUZILj5oiqV39CR1BAx1B9LKE
vHNgei/wnSzscoi+je9it1HUpZZLo/nL2KeO26OVSQumeipHNL6SbogKNcFDhScx2uuEnH+18oDu
vbUlk6sYqqUhux/6SPvDPNDlav5rjqqD8kgwmHtZYTF5TqICrU4dA8b6aw8ezUTU2qXmAJWaA1Yn
T3xgaSQM6fzULI2ZB6PWoXYB4/5++1Md4d2etVEH2yXkZeJml4dMjMLCuh++PCtRsVZfOeCfPo86
12uLR1cYDixUbtoj3DNP+BiFcZIutmZYunauT5gaMHiTNAe4t2gYS+RiYxc20gwMAEg7IklRWwPz
RC4+dmHjDEsBwFDGjmnNSFZ5M1Kp2OsK67tCGbQ6ELca1KKGnQVhHDJsCsYDSSzOOgZIQEGXFsa7
hXMD8nJWDpYSAPYEhlYf4K9eN80hPb96R1jpE7TddXMIBW3v5RTveLila6NaU1YK77mWoHqq1af5
KLan1D5B20NhR6Jhy2qCtresLQrabryOI9JtAeHbZ8Mwf3Udy1R5ogsnNSHSYV0KJ50UIYK+7kLL
cuoiS27dilWaJmcuaLvjNmleyaD+HMojxMDvZYCJtbqjg8r91YkRZl2YFop7nhCVhNg+7P6u6+JO
HAf32qDtrgUVCNrexyleOURYHy56tbGsIqsEUH5Bqvs3MnKMBg7ScGw928k9XVLktX4iyGlR0HYR
rgRNjQhGCtoe84dG+PalqV7ir07HCuCU8HUvrUuykxo7Yqn3rCI2NEH49oWpXuSvPtbUAS16hvil
1QZtT3c1OjBJWS7hB9tE+PalDZisqnH8051QF94td1dzibE2FEfArUuvoO2CRh4mtKo3DnooYGJx
bVR3QowLGjJZ7Gjr3Qy5EQw9eJ748dL9AO6GHevWZUDQdktCJGi705uK5NomSpG153yXgvDtM2H0
t6XhpV3WcjMRtH1/8f+dTC47ZWU5AwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2008-10-17 22:52:31 +0100" MODIFIED_BY="Uyen H Kao" NO="6" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Any pharmacological treatment versus Placebo, outcome: 1.3 Average score in withdrawal symptoms.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvsAAAEgCAMAAAAdTkwNAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2008-10-17 22:52:28 +0100" MODIFIED_BY="Uyen H Kao" NO="7" REF_ID="CMP-001.04" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Any pharmacological treatment versus Placebo, outcome: 1.4 Average score in craving.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtQAAACACAMAAAAccw4KAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-21 22:11:39 +0100" MODIFIED_BY="Uyen H Kao">
<APPENDIX ID="APP-01" MODIFIED="2008-10-17 17:50:43 +0100" MODIFIED_BY="Uyen H Kao" NO="1">
<TITLE MODIFIED="2008-10-17 17:42:19 +0100" MODIFIED_BY="Uyen H Kao">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-17 17:50:43 +0100" MODIFIED_BY="Uyen H Kao">
<OL>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled trial.pt.</LI>
<LI>randomized controlled trials/</LI>
<LI>controlled clinical trials/</LI>
<LI>random$.ti,ab.</LI>
<LI>Double-blind method/ or Random allocation/</LI>
<LI>single blind method/</LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$).mp.[mp=title, abstract, registry number word, mesh subject heading]</LI>
<LI>clinical trial.pt.</LI>
<LI>clinical trials/</LI>
<LI>(clinical adj trial$).ti,ab.</LI>
<LI>placebos/</LI>
<LI>placebo$,ti,ab.</LI>
<LI>research design/</LI>
<LI>exp evaluation studies/</LI>
<LI>follow-up studies/</LI>
<LI>follow up.ti,ab.</LI>
<LI>prospective studies/</LI>
<LI>(control$ or prospectiv$ or volunteer$).ti,ab.</LI>
<LI>or/1-19</LI>
<LI>amphetamine/ or dextroamphetamine/ or methamphetamine/</LI>
<LI>(amphetamine or methamphetamine or dextroamphetamine).ti,ab.</LI>
<LI>21 or 22</LI>
<LI>exp substance-related disorders/dt,px,rh,th [Drug Therapy, Psychology, Rehabilitation, Therapy]</LI>
<LI>20 and 23 and 24</LI>
<LI>limit 25 to human</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-10-21 22:07:18 +0100" MODIFIED_BY="Uyen H Kao" NO="2">
<TITLE MODIFIED="2008-10-17 17:43:24 +0100" MODIFIED_BY="Uyen H Kao">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-17 17:46:56 +0100" MODIFIED_BY="Uyen H Kao">
<OL>
<LI>amphetamines/</LI>
<LI>amphetamine/</LI>
<LI>dextroamphetamine/</LI>
<LI>methamphetamine/</LI>
<LI>or/1-2</LI>
<LI>dependence/</LI>
<LI>abuse/</LI>
<LI>psychosis</LI>
<LI>withdrawal</LI>
<LI>or/6-9</LI>
<LI>5 and 10</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-10-21 22:11:39 +0100" MODIFIED_BY="Uyen H Kao" NO="3">
<TITLE MODIFIED="2008-10-21 22:11:39 +0100" MODIFIED_BY="Uyen H Kao">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-17 17:46:25 +0100" MODIFIED_BY="Uyen H Kao">
<OL>
<LI>exp Clinical Trials/</LI>
<LI>exp Drug Therapy/</LI>
<LI>exp Longitudinal Studies/</LI>
<LI>prospective studies/</LI>
<LI>controlled study.mp.</LI>
<LI>exp Followup Studies/</LI>
<LI>random$ trial$.mp.</LI>
<LI>controlled trial$.mp.</LI>
<LI>randomized controlled trial.mp.</LI>
<LI>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9</LI>
<LI>exp AMPHETAMINE/</LI>
<LI>exp METHAMPHETAMINE/</LI>
<LI>exp Dextroamphetamine/</LI>
<LI>11 or 12 or 13</LI>
<LI>exp Drug Abuse/</LI>
<LI>exp Drug Dependency/</LI>
<LI>15 or 16</LI>
<LI>exp Drug Withdrawal/</LI>
<LI>exp PSYCHOSIS/</LI>
<LI>17 or 18 or 19</LI>
<LI>14 and 20</LI>
<LI>10 and 21</LI>
<LI>limit 22 to human (135)</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>